

http://www.aimspress.com/journal/MBE

MBE, 17(5): 4678–4705. DOI: 10.3934/mbe.2020257 Received: 09 May 2020 Accepted: 03 July 2020 Published: 08 July 2020

# Research article

# Global dynamics of a delayed diffusive virus infection model with cell-mediated immunity and cell-to-cell transmission

Chunyang Qin<sup>1</sup>, Yuming Chen<sup>2</sup> and Xia Wang<sup>1,3,\*</sup>

<sup>1</sup> School of Mathematics and Statistics, Xinyang Normal University, Xinyang 464000, China

<sup>2</sup> Department of Mathematics, Wilfrid Laurier University, Waterloo N2L 3C5, Canada

- <sup>3</sup> College of Mathematics and Information Science, Henan Normal University, Xinxiang 453000, China
- \* Correspondence: Email: xywangxia@163.com.

**Abstract:** In this paper, we propose and analyze a delayed diffusive viral dynamic model incorporating cell-mediated immunity and both cell-free and cell-to-cell transmission. After discussing the well-posedness, we provide some preliminary results on solutions. Then we study the existence and uniqueness of homogeneous steady states, which turned out to be completely determined by the basic reproduction number of infection  $R_0$  and the basic reproduction number of immunity  $R_1$ . Note that when  $R_1$  is defined, it is necessary that  $R_0 > 1$ . The main result is a threefold dynamics. Roughly speaking, when  $R_0 < 1$  the infection-free steady state is globally asymptotically stable; when  $R_1 > 1$  the infected-immune steady state is globally asymptotically stable. The approaches are linearization technique and the Lyapunov functional method. The theoretical results are also illustrated with numerical simulations.

**Keywords:** cell-mediated immunity; cell-to-cell transmission; spatial heterogeneity; delay; global stability

# 1. Introduction

Viral dynamics is a field of applied mathematics which employs mathematical models to describe the changes over time of infected cells and the viral load. Nowak et al. [1] and Nowak and May [2] proposed the following basic viral dynamic model,

$$\begin{cases} \frac{du(t)}{dt} = s - du(t) - \beta u(t)v(t), \\ \frac{dw(t)}{dt} = \beta u(t)v(t) - \delta w(t), \\ \frac{dv(t)}{dt} = N\delta w(t) - cv(t), \end{cases}$$
(1.1)

where u(t), w(t), and v(t) are the numbers of uninfected cells, productively infected cells, and virus particles at time *t*, respectively. See the references for the biological meanings of the parameters. This basic model has been modified to study different viral infections, which include hepatitis C virus (HCV) [3, 4], human immunodeficiency virus (HIV) [5–8], human T-cell leukemia virus (HTLV) [9–11], and so on.

During the process of viral infection, specific immune response plays an important role. Specific immune response includes cell-mediated immunity (which depends on cytotoxic T lymphocytes response (CTLs)) and humoral immunity (which depends on antibody response). Since the work of Nowak and Bangham [12], much has been done on mathematical models on immune response against infected cells [13–16].

Nowadays, time delays have been taken into account in order to better understand viral dynamics. Usually, distributed time delays [17–19] and discrete time delays [20–22] have been incorporated into viral dynamic models. In particular, based on (1.1), Zhu and Zou [20] proposed the following viral dynamic model with time delay and CTL immune response,

$$\begin{cases} \frac{du(t)}{dt} = s - du(t) - \beta u(t)v(t), \\ \frac{dw(t)}{dt} = \beta e^{-m\hat{\tau}}u(t - \hat{\tau})v(t - \hat{\tau}) - \delta w(t) - pw(t)z(t), \\ \frac{dv(t)}{dt} = N\delta w(t) - cv(t), \\ \frac{dz(t)}{dt} = qw(t)z(t) - bz(t), \end{cases}$$
(1.2)

where z(t) denotes the density of immune effectors at time t. Here the delay  $\hat{\tau}$  represents the time from a virus entering a target cell to the production of new free virus particles. We refer to [20] for the meanings of the other parameters.

Note that both models (1.1) and (1.2) and most existing ones are described by ordinary differential equations. The cells and free virus particles are assumed to be uniform in location. In other words, the effect of spatial heterogeneity is ignored. For example, the lymphoid tissues are among the primary sites of HIV infection and replication. The lymphoid tissues consist of many lymph nodes with different sizes. The different tissue architecture and composition and biophysical parameters can influence the spread and replication of the virus [23]. To understand the viral pathogenesis better, it is necessary to consider the spatial aspects of the tissues. In [24], Wang and Wang proposed the

following mathematical model of HBV infection with spatial dependence,

$$\begin{cases} \frac{\partial u(x,t)}{\partial t} = s - du(x,t) - \beta u(x,t)v(x,t), \\ \frac{\partial w(x,t)}{\partial t} = \beta u(x,t)v(x,t) - \delta w(x,t), \\ \frac{\partial v(x,t)}{\partial t} = D\Delta v(x,t) + N\delta w(x,t) - cv(x,t), \end{cases}$$
(1.3)

where u(x, t), w(x, t), and v(x, t) are the densities of uninfected cells, productively infected cells, and free virus particles at spatial position x and time t, respectively. D is the diffusion coefficient and  $\Delta$  is the Laplace operator. Using the geometric singular perturbation method, they studied the existence of traveling waves. Since then a lot of works have followed in this direction (see, for example, [25–29]).

In (1.1), (1.2), and (1.3), only the cell-free transmission (newly released free virus particles infect uninfected cells [2]) is considered. Recent experimental studies [30, 31] prove that a healthy cell can be infected when it comes with close contact of an infected cell (cell-to-cell transmission [32, 33]). Sigal et al. [34] found that the cell-to-cell spread of HIV can still permit ongoing replication even with an antiretroviral therapy. Consequently, viral dynamic models incorporating both transmission modes have been formulated and studied (to name a few, see [35–39]). We should mention that the incidences in these works are bilinear. Incidence is the number of new infections per unit of time. It depends on the infectivity of viruses and behavior of cells. Thus it is reasonable to be nonlinear in general. For example, the saturated incidence rate  $\frac{\beta uv}{1+av}$  is used in [40] and the Beddington-DeAngelis incidence function is used in [41]. In a recent work, Sun and Wang [42] also used a general incidence f(u, v) in a diffusive viral dynamic model.

Based on the above discussion, in this paper, we propose and study the following delayed diffusive viral dynamic model with cell-mediated immunity, cell-to-cell transmission, and general incidences,

$$\begin{cases} \frac{\partial u(x,t)}{\partial t} = s - du(x,t) - f(u(x,t),v(x,t)) - g(u(x,t),w(x,t)),\\ \frac{\partial w(x,t)}{\partial t} = e^{-m\tau}f(u(x,t-\tau),v(x,t-\tau)) + e^{-m\tau}g(u(x,t-\tau),w(x,t-\tau))\\ -\delta w(x,t) - pw(x,t)z(x,t),\\ \frac{\partial v(x,t)}{\partial t} = D_1\Delta v(x,t) + N\delta w(x,t) - cv(x,t), \ x \in \Omega, \ t > 0,\\ \frac{\partial z(x,t)}{\partial t} = D_2\Delta z(x,t) + qw(x,t)z(x,t) - bz(x,t), \ x \in \Omega, \ t > 0, \end{cases}$$
(1.4)

where z(x, t) denotes the densities of immune effectors at spatial position x and time t.  $\Omega$  is a general open bounded domain in  $\mathbb{R}^n$  with smooth boundary  $\partial \Omega$ . We consider model (1.4) with the homogeneous Neumann boundary conditions

$$\frac{\partial v}{\partial \vec{n}} = 0, \ \frac{\partial z}{\partial \vec{n}} = 0, \ x \in \partial \Omega, \ t > 0,$$
(1.5)

where  $\frac{\partial}{\partial \vec{n}}$  denotes the outward normal derivative on  $\partial \Omega$ . We also assume the initial conditions

$$u(x,\theta) = \phi_1(x,\theta) \ge 0, \ w(x,\theta) = \phi_2(x,\theta) \ge 0,$$
  

$$v(x,\theta) = \phi_3(x,\theta) \ge 0, \ z(x,\theta) = \phi_4(x,\theta) \ge 0, \ (x,\theta) \in \overline{\Omega} \times [-\tau,0],$$
(1.6)

Mathematical Biosciences and Engineering

where  $\phi_i$ 's (i = 1, 2, 3, 4) are bounded and uniformly continuous functions on  $\overline{\Omega} \times [-\tau, 0]$ .

In (1.4), intracellular delays for both transmission modes are assumed to be the same. In general, the intracellular delay in the cell-to-cell transmission is less than that in the cell-free infection [30, 39]. However, the difference is not large enough. As for some existing studies (for example, [35, 38]), for simplicity of presentation, we make the above assumption on the delays.

In (1.4), the incidences due to the cell-free transmission and the cell-to-cell transmission are given by the nonlinear functions f(u, v) and g(u, w), respectively. As in [26], we always make the following assumption on them in the sequel.

(A1) The nonlinear incidence functions f and g satisfy the following properties.

- (i)  $f(u, v) \ge 0$  and  $g(u, w) \ge 0$  for  $u \ge 0$ ,  $v \ge 0$ , and  $w \ge 0$ , and the equalities hold if and only if uv = 0 and uw = 0;
- (ii) There exists  $\eta_1 > 0$  and  $\eta_2 > 0$  such that  $f(u, v) \le \eta_1 u$  and  $g(u, w) \le \eta_2 u$  for  $u \ge 0, v \ge 0$ , and  $w \ge 0$ ;
- (iii)  $\frac{\partial f(u,v)}{\partial u}$  and  $\frac{\partial g(u,w)}{\partial u}$  are continuous with  $\frac{\partial f(u,v)}{\partial u} > 0$  and  $\frac{\partial g(u,w)}{\partial u} > 0$  for  $u \ge 0$ , v > 0, and w > 0; (iv)  $\frac{\partial f(u,v)}{\partial v}$  and  $\frac{\partial g(u,w)}{\partial w}$  are continuous with  $\frac{\partial f(u,v)}{\partial v} \ge 0$  and  $\frac{\partial g(u,w)}{\partial w} \ge 0$  for  $u \ge 0$ ,  $v \ge 0$ , and  $w \ge 0$ ; (v)  $v \frac{\partial f(u,v)}{\partial v} f(u,v) \le 0$  and  $w \frac{\partial g(u,w)}{\partial w} g(u,w) \le 0$  for  $u \ge 0$ ,  $v \ge 0$ , and  $w \ge 0$ ;

Note that, by Assumption (A1), for any u > 0,

$$\frac{\partial(\frac{f(u,v)}{v})}{\partial v} = \frac{\frac{\partial f(u,v)}{\partial v}v - f(u,v)}{v^2} < 0,$$

which implies that  $\frac{f(u,v)}{v}$  is decreasing on  $(0,\infty)$ . In particular, for any u > 0 and v > 0,

$$\frac{f(u,v)}{v} \le \lim_{v \to 0^+} \frac{f(u,v)}{v} = \frac{\partial f(u,0)}{\partial v}$$

An analog also holds for g. Thus we have

$$f(u,v) \le \frac{\partial f(u,0)}{\partial v} v \text{ and } g(u,w) \le \frac{\partial g(u,0)}{\partial w} w \text{ for } u \ge 0, v \ge 0, \text{ and } w \ge 0.$$
 (1.7)

The rest of the paper is organized as follows. In section 2, we consider the existence, uniqueness, positivity, and boundedness of solutions to system (1.4)-(1.6). Then we study the existence of homogeneous steady states in section 3, which depend on the basic reproduction number of infection and the basic reproduction number of immunity. The main part is section 4, where we discuss the local and global dynamics of system (1.4)–(1.6) by analyzing the characteristic equations and constructing suitable Lyapunov functionals. These results are supported with numerical simulations in section 5. The paper ends with a brief conclusion.

## 2. Well-posedness

Let  $\mathbf{X} := C(\overline{\Omega}, \mathbb{R}^4)$  be the Banach space equipped with the supremum norm  $\|\cdot\|_{\mathbf{X}}$ . For  $\tau \ge 0$ , define  $C = C([-\tau, 0], \mathbf{X})$ , which is a Banach space equipped with the norm  $\|\phi\| = \max_{\theta \in [-\tau, 0]} \|\phi(\theta)\|_{\mathbf{X}}$ . If  $\sigma > 0$ and  $U: [-\tau, \sigma) \to \mathbf{X}$ , then for  $t \in [0, \sigma)$ ,  $U_t \in C$  is defined by  $U_t(\theta) = U(t + \theta)$  for  $\theta \in [-\tau, 0]$ . Denote  $\mathbf{X}^+ = C(\overline{\Omega}, \mathbb{R}^4_+)$  and  $C^+ = C([-\tau, 0], \mathbf{X}^+)$ . Then both  $(\mathbf{X}, \mathbf{X}^+)$  and  $(C, C^+)$  are strongly ordered spaces. According to Corollary 4 in [43], we have the following result on the well-posedness. The arguments are standard and hence are omitted here. Interested readers can refer to, for example, a recent paper by Gao and Wang [44].

**Theorem 2.1.** For each  $\phi = (\phi_1, \phi_2, \phi_3, \phi_4) \in C^+$ , system (1.4)–(1.6) has a unique solution  $U(\cdot, t, \phi) = (u(\cdot, t, \phi), w(\cdot, t, \phi), v(\cdot, t, \phi), z(\cdot, t, \phi))$  on  $[0, \infty)$  with  $U_0(\cdot, \phi) = \phi$ . Moreover,  $U_t(\cdot, \phi) \in C^+$  for  $t \ge 0$  and  $U(\cdot, t, \phi)$  is a classical solution.

Let  $\Phi(t) : C^+ \to C^+$  be the solution semiflow associated with (1.4)–(1.6), that is,  $\Phi(t, \phi) = U_t(\cdot, \phi)$ , where  $U(\cdot, t, \phi)$  is the solution of (1.4)–(1.6) with the initial condition  $\phi \in C^+$ .

The following result gives some properties of solutions.

**Lemma 2.2.** For  $\phi \in C^+$ , the following statements hold for the solution  $U(\cdot, t, \phi)$  of (1.4)–(1.6).

- (i)  $\limsup_{t \to \infty} u(x, t, \phi) \leq \frac{s}{d}, \qquad \limsup_{t \to \infty} w(x, t, \phi) \leq \frac{e^{-m\tau}(\eta_1 + \eta_2)s}{d\delta}, \qquad \limsup_{t \to \infty} v(x, t, \phi) \leq \frac{Ne^{-m\tau}(\eta_1 + \eta_2)s}{dc}, \quad and \qquad \limsup_{t \to \infty} z(x, t, \phi) \leq \frac{e^{-m\tau}(\eta_1 + \eta_2)s}{d\min\{\delta, b\}} \text{ uniformly for all } x \in \Omega.$
- (ii)  $u(\cdot, t, \phi) > 0$  for t > 0 and  $\liminf_{t \to \infty} u(x, t, \phi) \ge \frac{s}{d + \eta_1 + \eta_2}$  uniformly for all  $x \in \Omega$ .
- (iii) If  $w(\cdot, t_0, \phi) \neq 0$  or  $v(\cdot, t_0, \phi) \neq 0$  for some  $t_0 \ge 0$ , then  $w(x, t, \phi) > 0$  and  $v(x, t, \phi) > 0$  for all  $x \in \Omega$ and  $t > t_0 + \tau$ .
- (iv) If  $z(\cdot, t_0, \phi) \neq 0$  for some  $t_0 \ge 0$ , then  $z(x, t, \phi) > 0$  for all  $x \in \Omega$  and  $t > t_0$ .
- *Proof.* For simplicity of notation, in the proof here we omit  $\phi$  from the expressions of the solution. (i) First, we have

$$\frac{\partial u(x,t)}{\partial t} \le s - du(x,t),$$

which implies that  $\limsup_{t\to\infty} u(x,t) \le \frac{s}{d}$  uniformly for all  $x \in \Omega$ . Next, by Assumption (A1) and the second equation in (1.4), we have

$$\frac{\partial w(x,t)}{\partial t} \le e^{-m\tau} (\eta_1 + \eta_2) u(x,t) - \delta w(x,t).$$

Then  $\limsup_{t\to\infty} w(x,t) \le \frac{e^{-mt}(\eta_1+\eta_2)s}{d\delta}$  uniformly for  $x \in \Omega$  follows easily from this and  $\limsup_{t\to\infty} u(x,t) \le \frac{s}{d}$  uniformly for  $x \in \Omega$ . Similarly, adding the second and fourth equations of (1.4) yields

$$\frac{\partial(w(x,t)+z(x,t))}{\partial t} \le e^{-m\tau}(\eta_1+\eta_2)u(x,t) - \min\{\delta,b\}(w(x,t)+z(x,t)).$$

It follows that  $\limsup_{t\to\infty} (w(x,t) + z(x,t)) \leq \frac{e^{-m\tau}(\eta_1 + \eta_2)s}{d\min\{\delta,b\}}$  uniformly for  $x \in \Omega$  and hence  $\limsup_{t\to\infty} z(x,t) \leq \frac{e^{-m\tau}(\eta_1 + \eta_2)s}{d\min\{\delta,b\}}$  uniformly for  $x \in \Omega$ . Now,  $\limsup_{t\to\infty} w(x,t) \leq \frac{e^{-m\tau}(\eta_1 + \eta_2)s}{d\delta}$  uniformly for  $x \in \Omega$  together with the third equation of (1.4) (Lemma 1 in [45]), and comparison theorem, gives  $\limsup_{t\to\infty} v(x,t) \leq \frac{Ne^{-m\tau}(\eta_1 + \eta_2)s}{dc}$  uniformly for  $x \in \Omega$ .

(ii) Noting that  $\frac{\partial u(x,t)}{\partial t} \ge s - (d + \eta_1 + \eta_2)u(x,t)$ , one can easily get

$$u(x,t) \ge e^{-(d+\eta_1+\eta_2)t}u(x,0) + \frac{s}{d+\eta_1+\eta_2} - \frac{e^{-(d+\eta_1+\eta_2)t}s}{d+\eta_1+\eta_2}$$

Mathematical Biosciences and Engineering

for  $x \in \Omega$  and  $t \ge 0$ . Then (ii) follows immediately.

(iii) Note that the operator  $D_1\Delta - c$ Id generates a positive semigroup on  $C(\overline{\Omega}, \mathbb{R})$ , where Id is the identity operator. Thus if  $w(\cdot, t_0) \neq 0$ , then from the third equation of (1.4), we see that  $v(\cdot, t) \neq 0$  for  $t > t_0$ . Without loss of generality, we assume that  $v(\cdot, t_0) \neq 0$ . We first show that  $v(\cdot, t) > 0$  for  $t > t_0$ . By Theorem 2.1, v(x, t) satisfies

$$\begin{cases} \frac{\partial v(x,t)}{\partial t} \ge D_1 \Delta v(x,t) - cv(x,t), & t > t_0, \ x \in \Omega, \\ \frac{\partial v(x,t)}{\partial t} = 0, & t > t_0, \ x \in \partial \Omega. \end{cases}$$

Let  $\overline{v}(x, t)$  be the solution of

$$\begin{cases} \frac{\partial \bar{v}(x,t)}{\partial t} = D_1 \Delta \bar{v}(x,t) - c \bar{v}(x,t), & t > t_0, \ x \in \Omega, \\ \frac{\partial \bar{v}(x,t)}{\partial \vec{n}} = 0, & t > t_0, \ x \in \partial \Omega, \\ \bar{v}(x,t_0) = v(x,t_0), \ x \in \overline{\Omega}. \end{cases}$$

Then  $\bar{v}(x,t) > 0$  for  $x \in \Omega$  and  $t > t_0$ . In fact, suppose, by contradiction, there exist  $x_0 \in \Omega$  and  $\hat{t} > t_0$ such that  $\bar{v}(x_0, \hat{t}) = 0$ . Then, according to the strong maximum principle [46],  $\bar{v}(x,t) \equiv 0$  for each  $t \ge t_0$ , contradicting with  $\bar{v}(\cdot, t_0) \not\equiv 0$ . Applying the comparison theorem, we know that  $v(x,t) \ge \bar{v}(x,t) > 0$  for  $t > t_0$  and  $x \in \Omega$ . We now prove that w(x,t) > 0 for  $x \in \Omega$  and  $t > t_0 + \tau$ . Otherwise, there exist  $\bar{x} \in \Omega$ and  $\bar{t} > t_0 + \tau$  such that  $w(\bar{x}, \bar{t}) = 0$ . As  $w(x, t) \ge 0$ , we have  $\frac{\partial w(\bar{x}, \bar{t})}{\partial t} = 0$ . This is impossible since

$$\frac{\partial w(\bar{x},\bar{t})}{\partial t} = e^{-m\tau} f(u(\bar{x},\bar{t}-\tau),v(\bar{x},\bar{t}-\tau)) + e^{-m\tau} g(u(\bar{x},\bar{t}-\tau),w(\bar{x},\bar{t}-\tau)) > 0$$

by Assumption (A1) (ii) due to  $u(\bar{x}, \bar{t} - \tau) > 0$  and  $v(\bar{x}, \bar{t} - \tau) > 0$ . This proves statement (iii).

(iv) The proof is similar to that of (iii) on v(x, t) > 0 for  $x \in \Omega$  and  $t > t_0$  and hence we omit it here. This completes the proof.

Lemma 2.2 tells us that  $\Phi$  is point dissipative. Then it follows from Theorem 2.1.8 in [47] that  $\Phi(t)$  is compact for all  $t > \tau$ . This, together with Theorem 3.4.8 in [48], gives the following result.

**Theorem 2.3.** The semiflow  $\Phi$  has a global compact attractor  $\mathcal{A}$  in  $C^+$ . Moreover,  $u(x, t, \phi) \leq \frac{s}{d}$  for all  $x \in \overline{\Omega}, t \geq 0$ , and  $\phi \in \mathcal{A}$ .

#### 3. Steady states and basic reproduction numbers

System (1.4) with (1.5) always has a unique infection-free steady state  $P_0 = (u_0, 0, 0, 0)$ , where  $u_0 = s/d$ . Applying the result of Wang and Zhao (Theorem 3.4 in [49]), we can obtain the expression of the basic reproduction number of infection,  $R_0$ , which is given by

$$R_0 = \frac{Ne^{-m\tau}}{c} \cdot \frac{\partial f(\frac{s}{d}, 0)}{\partial v} + \frac{e^{-m\tau}}{\delta} \cdot \frac{\partial g(\frac{s}{d}, 0)}{\partial w}$$

Denote

$$R_{01} = \frac{Ne^{-m\tau}}{c} \cdot \frac{\partial f(\frac{s}{d}, 0)}{\partial v} \quad \text{and} \quad R_{02} = \frac{e^{-m\tau}}{\delta} \cdot \frac{\partial g(\frac{s}{d}, 0)}{\partial w}.$$

Mathematical Biosciences and Engineering

Then  $R_{01}$  is the number of secondly infected cells through the cell-free transmission and it is referred to as the basic reproduction number from the cell-free transmission; while  $R_{02}$  is the number of secondly infected cells through the cell-to-cell transmission and it is referred to as the basic reproduction number from the cell-to-cell transmission [38].

In the following, we discuss the existence of homogeneous steady states for (1.4) (the stability results in section 4 indicate that they are the only possible steady states). Clearly, a homogeneous steady state P = (u, w, v, z) satisfies

$$s - du - f(u, v) - g(u, w) = 0, (3.1a)$$

$$f(u, v)e^{-m\tau} + g(u, w)e^{-m\tau} - \delta w - pwz = 0,$$
 (3.1b)

$$N\delta w - cv = 0, \tag{3.1c}$$

$$qwz - bz = 0. \tag{3.1d}$$

It follows from (3.1d) that z = 0 (which corresponds to the immunity-free infected steady states) or  $w = \frac{b}{q}$  (which, when  $z \neq 0$ , corresponds to the infected-immune steady states).

We firstly consider the case where z = 0. It follows from (3.1c) that  $v = \frac{N\delta w}{c}$ . Multiplying both sides of (3.1b) by  $e^{m\tau}$  and then adding up the resultant and (3.1a) to get  $u = \frac{s - \delta w e^{m\tau}}{d}$ . It is necessary that  $w \in (0, \frac{s}{\delta e^{m\tau}})$ . Substituting  $u = \frac{s - \delta w e^{m\tau}}{d}$  and  $v = \frac{N\delta w}{c}$  into (3.1a), we see that w is a positive zero of  $H_1$ , where

$$H_1(w) = f\left(\frac{s - \delta w e^{m\tau}}{d}, \frac{N\delta w}{c}\right) + g\left(\frac{s - \delta w e^{m\tau}}{d}, w\right) - \delta w e^{m\tau}.$$
(3.2)

According to Assumption (A1), we have  $H_1(0) = 0$ ,  $H_1(\frac{s}{\delta e^{m\tau}}) - s < 0$ , and

$$H_1'(0) = \delta e^{m\tau} \left( \frac{N e^{-m\tau}}{c} \cdot \frac{\partial f(\frac{s}{d}, 0)}{\partial v} + \frac{e^{-m\tau}}{\delta} \cdot \frac{\partial g(\frac{s}{d}, 0)}{\partial w} \right) - \delta e^{m\tau} = \delta e^{m\tau} (R_0 - 1).$$

If  $R_0 > 1$ , then  $H'_1(0) > 0$ . This, together with  $H_1(0) = 0$ , implies that  $H_1(w)$  is positive for all sufficiently small w > 0. By the Intermediate Value Theorem,  $H_1$  has at least one zero in  $(0, \frac{s}{\delta e^{m\tau}})$  and hence (1.4) has at least one immunity-free infected steady state. In fact, there is only one such steady state by the claim that  $H'_1(w_1) < 0$  for any immunity-free infected steady state, which is proved as follows. Note that  $\delta e^{m\tau} = \frac{f(u_1, v_1)}{w_1} + \frac{g(u_1, w_1)}{w_1}$  and  $w_1 = \frac{cv_1}{N\delta}$ . By Assumption (A1),

$$H_{1}'(w_{1}) = -\frac{\delta e^{m\tau}}{d} \frac{\partial f(u_{1}, v_{1})}{\partial u} + \frac{N\delta}{c} \frac{\partial f(u_{1}, v_{1})}{\partial v} - \frac{\delta e^{m\tau}}{d} \frac{\partial g(u_{1}, w_{1})}{\partial u} + \frac{\partial g(u_{1}, w_{1})}{\partial w} - \frac{N\delta}{cv_{1}} f(u_{1}, v_{1}) - \frac{1}{w_{1}} g(u_{1}, w_{1}) = -\frac{\delta e^{m\tau}}{d} \frac{\partial f(u_{1}, v_{1})}{\partial u} - \frac{\delta e^{m\tau}}{d} \frac{\partial g(u_{1}, w_{1})}{\partial u} + \frac{N\delta}{cv_{1}} \left( v_{1} \frac{\partial f(u_{1}, v_{1})}{\partial v} - f(u_{1}, v_{1}) \right) + \frac{1}{w_{1}} \left( w_{1} \frac{\partial g(u_{1}, w_{1})}{\partial w} - g(u_{1}, w_{1}) \right) < 0.$$

This proves the claim. Next, we assume that  $R_0 < 1$ . Then  $H'_1(0) = \delta e^{m\tau}(R_0 - 1) < 0$ , which combined with  $H_1(0) = 0$  implies that  $H_1(w) < 0$  for w > 0 sufficiently small. Using the above

claim, we can easily see that there is no immunity-free infected steady state when  $R_0 < 1$ . Moreover,  $H_1(w) < 0$  for  $w \in (0, \frac{s}{\delta e^{m\pi}}]$ . Finally, we assume that  $R_0 = 1$ . We use contradictive arguments to show that there is no immunity-free infected steady state in this case. Otherwise, assume that  $H_1(w)$  has a positive zero say  $w^*$ . Then from the above claim  $H_1(w) > 0$  for  $w < w^*$  and closely enough to  $w^*$ . Note that  $H_1(w)$  depends continuously on the parameters and  $H_1(w) < 0$  for  $w \in (0, \frac{s}{\delta e^{m\pi}}]$  when  $R_0 < 1$ . Fix  $w \in (0, w^*)$ . Choose a sequence of parameters such that the basic reproduction number  $R_0 < 1$  and tends to 1. Then  $H_1(w)$  tends to  $H_1(w^*) > 0$ , a contradiction to the fact that the limit is less than or equal to 0. This proves that there is no immunity-free infected steady state when  $R_0 = 1$ .

Now we study the case where  $w = \frac{b}{q}$ . This, together with (3.1c), yields  $v = \frac{N\delta b}{cq}$ . As before, add up (3.1a) and (3.1b) multiplied by  $e^{m\tau}$  to get  $z = \frac{s-du-\delta e^{m\tau}w}{pe^{m\tau}w}$ , which necessarily requires  $u \in (0, \frac{s}{d} - \frac{\delta b}{dq}e^{m\tau})$ . Substituting  $w = \frac{b}{q}$  and  $z = \frac{s-du-\delta e^{m\tau}w}{pe^{m\tau}w}$  into (3.1a), we see that u is a positive zero of  $H_2$ , where

$$H_2(u) = f\left(u, \frac{N\delta b}{cq}\right) + g\left(u, \frac{b}{q}\right) - s + du.$$
(3.3)

With Assumption (A1), we have  $H_2(0) = -s < 0$  and

$$H_2'(u) = \frac{\partial f(u, \frac{N\delta b}{cq})}{\partial u} + \frac{\partial g(u, \frac{b}{q})}{\partial u} + d > 0.$$

Therefore, in order for model (1.4) to have an infected-immune steady state (if exists there is a unique one), it is necessary and sufficient that  $H_2(\frac{s}{d} - \frac{\delta b}{dq}e^{m\tau}) = H_1(\frac{b}{q}) > 0$ . Recall that when  $R_0 \le 1$ ,  $H_1(w) < 0$  for  $w \in (0, \frac{s}{\delta e^{m\tau}}]$ ; while when  $R_0 > 1$ ,  $H_1(w) > 0$  for  $w \in (0, w_1)$  and  $H_1(w) < 0$  for  $w \in (w_1, \frac{s}{\delta e^{m\tau}})$ . It follows that  $H_1(\frac{b}{q}) > 0$  if and only if  $R_0 > 1$  and  $\frac{b}{q} < w_1$ . Denote,

$$R_1 = \frac{qw_1}{b}.$$

As q is the average number of immune effectors produced from contacting with a productively infected cell and  $\frac{1}{b}$  is the average life of an immune effector, it follows that  $R_1$  is the total number of immune effectors produced at the immunity-free infected steady state. Thus  $R_1$  is called the basic reproduction number of immunity.

Summarizing the above discussion, we have obtained the following result on the existence of homogeneous steady states.

**Theorem 3.1.** For model (1.4) with (1.5), the following statements on the existence of homogeneous steady states are true.

- (i) If  $R_0 \leq 1$ , then there is only the infection-free steady state  $P_0$ .
- (ii) If  $R_1 \le 1 < R_0$ , then besides  $P_0$ , there is also a unique immunity-free infected steady state  $P_1 = (u_1, w_1, v_1, 0)$ , where  $w_1$  is the only positive zero of  $H_1$  defined by (3.2),  $u_1 = \frac{s \delta w_1 e^{m\tau}}{d}$  and  $v_1 = \frac{N \delta w_1}{c}$ .
- (iii) If  $R_1 > 1$  (it is necessary that  $R_0 > 1$ ), then in addition to  $P_0$  and  $P_1$ , there is also a unique infected-immune steady state  $P_2 = (u_2, w_2, v_2, z_2)$ , where  $u_2$  is the only positive zero of  $H_2$  defined by (3.3),  $w_2 = \frac{b}{q}$ ,  $v_2 = \frac{N\delta b}{cq}$ , and  $z_2 = \frac{s-du_2-\delta w_2e^{m\tau}}{pw_2e^{m\tau}}$ .

#### 4. Stability analysis

In the main part of this paper, we establish the stability of each steady state obtained in Theorem 3.1. Let  $P^* = (u^*, w^*, v^*, z^*)$  be an arbitrary homogeneous steady state. The linearization of (1.4) at  $P^*$  is

$$\frac{\partial Q}{\partial t} = \mathbb{L}\Delta Q + AQ + BQ_{\tau}, \tag{4.1}$$

where

$$\begin{split} \mathbb{L} &= & \operatorname{diag}(0, 0, D_{1}, D_{2}), \\ Q &= & (u(x, t), w(x, t), v(x, t), z(x, t)), \\ Q_{\tau} &= & (u_{\tau}, w_{\tau}, v_{\tau}, z_{\tau}) = & (u(x, t - \tau), w(x, t - \tau), v(x, t - \tau), z(x, t - \tau)) \\ A &= & \begin{pmatrix} -d - \frac{\partial f(u^{*}, v^{*})}{\partial u} - \frac{\partial g(u^{*}, w^{*})}{\partial u} & -\frac{\partial g(u^{*}, w^{*})}{\partial w} & -\frac{\partial f(u^{*}, v^{*})}{\partial v} & 0 \\ 0 & -\delta - pz^{*} & 0 & -pw^{*} \\ 0 & N\delta & -c & 0 \\ 0 & qz^{*} & 0 & qw^{*} - b \end{pmatrix}, \\ B &= & \begin{pmatrix} 0 & 0 & 0 & 0 \\ \frac{\partial f(u^{*}, v^{*})}{\partial u} + \frac{\partial g(u^{*}, w^{*})}{\partial u} e^{-m\tau} & \frac{\partial g(u^{*}, w^{*})}{\partial w} e^{-m\tau} & \frac{\partial f(u^{*}, v^{*})}{\partial v} e^{-m\tau} & 0 \\ 0 & 0 & 0 & 0 \end{pmatrix}. \end{split}$$

Denote  $0 = \mu_0 < \mu_1 < \mu_2 < \cdots < \mu_n < \cdots$  to be all the eigenvalues of the operator  $-\Delta$  on  $\Omega$  with the homogeneous Neumann boundary condition. Then  $P^*$  is locally asymptotically stable if, for any  $i \in \mathbb{N} = \{0, 1, 2, \ldots\}$ , every solution of the characteristic equation

$$|\lambda E + \mu_i \mathbb{L} - A - Be^{-\lambda \tau}| = 0 \tag{4.2}$$

has a negative real part and  $P^*$  is unstable if there exists  $i_0 \in \mathbb{N}$  such that (4.2) has a solution with a positive real part.

## 4.1. Stability of the infection-free steady state $P_0$

We first study the local stability of  $P_0$ .

**Proposition 4.1.** The infection-free steady state  $P_0$  of (1.4) is locally asymptotically stable if  $R_0 < 1$  and unstable if  $R_0 > 1$ .

*Proof.* By (4.2), the characteristic equation at  $P_0$  is

$$(\lambda + b + \mu_i D_2)(\lambda + d) \left[ (\lambda + c + \mu_i D_1) \left( \lambda + \delta - \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-(\lambda + m)\tau} \right) - N \delta \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-(\lambda + m)\tau} \right] = 0.$$

Obviously, the stability of  $P_0$  is determined by

$$(\lambda + c + \mu_i D_1) \left( \lambda + \delta - \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-m\tau} e^{-\lambda\tau} \right) - N\delta \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-m\tau} e^{-\lambda\tau} = 0.$$
(4.3)

Mathematical Biosciences and Engineering

Firstly, suppose that  $R_0 < 1$ . We claim that all roots of (4.3) have negative real parts. Otherwise, there exists  $i_0 \in \mathbb{N}$  such that (4.3) has a root  $\lambda_0$  with  $\operatorname{Re}(\lambda_0) \ge 0$ . Then

$$1 = \frac{1}{\lambda_0 + \delta} \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-m\tau} e^{-\lambda_0 \tau} + \frac{N\delta}{(\lambda_0 + \delta)(\lambda_0 + c + \mu_{i_0} D_1)} \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-m\tau} e^{-\lambda_0 \tau}.$$

It follows that

$$1 = \left| \frac{1}{\lambda_{0} + \delta} \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-m\tau} e^{-\lambda_{0}\tau} + \frac{N\delta}{(\lambda_{0} + \delta)(\lambda_{0} + c + \mu_{i_{0}}D_{1})} \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-m\tau} e^{-\lambda_{0}\tau} \right|$$

$$\leq \left| \frac{1}{\lambda_{0} + \delta} \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-m\tau} e^{-\lambda_{0}\tau} \right| + \left| \frac{N\delta}{(\lambda_{0} + \delta)(\lambda_{0} + c + \mu_{i_{0}}D_{1})} \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-m\tau} e^{-\lambda_{0}\tau} \right|$$

$$\leq \frac{1}{\delta} \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-m\tau} + \frac{N}{c + \mu_{i_{0}}D_{1}} \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-m\tau}$$

$$\leq \frac{1}{\delta} \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-m\tau} + \frac{N}{c} \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-m\tau}$$

$$= R_{0},$$

a contradiction to  $R_0 < 1$ . This proves the claim and hence  $P_0$  is locally asymptotically stable when  $R_0 < 1$ .

Secondly, assume  $R_0 > 1$ . For  $i \in \mathbb{N}$ , denote

$$F(\lambda, i) = (\lambda + c + \mu_i D_1) \left( \lambda + \delta - \frac{\partial g(\frac{s}{d}, 0)}{\partial w} e^{-m\tau} e^{-\lambda\tau} \right) - N\delta \frac{\partial f(\frac{s}{d}, 0)}{\partial v} e^{-m\tau} e^{-\lambda\tau}$$

Recall that  $\mu_0 = 0$ . We have

$$F(0,0) = c\delta(1 - R_0) < 0$$

and

$$F(\lambda,0) = \lambda^2 + (c+\delta)\lambda + c\delta - \left(c\delta R_0 + \frac{\partial g(\frac{s}{d},0)}{\partial w}e^{m\tau}\right)e^{-\lambda\tau} \to \infty \text{ as } \lambda \to \infty.$$

By the Intermediate Value Theorem,  $F(\lambda, 0)$  has a positive zero and hence (4.3) has at least one positive zero for i = 0. This means that  $P_0$  is unstable when  $R_0 > 1$ .

In fact,  $P_0$  is globally stable if it is locally stable.

**Theorem 4.2.** If  $R_0 \leq 1$ , then the infection-free steady state  $P_0$  of (1.4) is globally attractive. In particular,  $P_0$  is globally asymptotically stable when  $R_0 < 1$ .

*Proof.* It suffices to show that  $P_0$  is globally attractive in  $\mathcal{A}$ . For this purpose, we consider the Lyapunov functional

$$W(t) = \int_{\Omega} \left( e^{m\tau} w(x,t) + \frac{1}{N} e^{m\tau} v(x,t) + \frac{p}{q} e^{m\tau} z(x,t) \right) dx + \int_{\Omega} \left( \int_{t-\tau}^{t} f(u(x,\theta), v(x,\theta)) d\theta + \int_{t-\tau}^{\infty} g(u(x,\theta), w(x,\theta)) d\theta \right) dx$$

Mathematical Biosciences and Engineering

Calculating the time derivative of W(t) along solutions of model (1.4), we have

$$\frac{\mathrm{d}W(t)}{\mathrm{d}t} = \int_{\Omega} \left( f(u(x,t),v(x,t)) - \frac{c}{N} e^{m\tau} v(x,t) - \frac{pb}{q} e^{m\tau} z(x,t) \right) \mathrm{d}x + \frac{1}{N} e^{m\tau} \int_{\Omega} D_1 \Delta v(x,t) \mathrm{d}x.$$

It follows from the homogeneous Neumann boundary condition (1.5) and the Divergence Theorem that

$$\int_{\Omega} \Delta v(x,t) dx = \int_{\partial \Omega} \frac{\partial v(x,t)}{\partial \vec{n}} dx = 0.$$

Moreover, by Theorem 2.3,  $u(x, t) \le \frac{s}{d}$  for  $x \in \Omega$  and  $t \ge 0$ . With the help of (1.7), for v(x, t) > 0, we have

$$f(u(x,t),v(x,t)) - \frac{c}{N}e^{m\tau}v(x,t) = \frac{c}{N}e^{m\tau}v(x,t)\left(\frac{N}{c}e^{-m\tau}\frac{f(u(x,t),v(x,t))}{v(x,t)} - 1\right)$$

$$\leq \frac{c}{N}e^{m\tau}v(x,t)\left(\frac{N}{c}e^{-m\tau}\frac{f(\frac{s}{d},v(x,t))}{v(x,t)} - 1\right)$$

$$\leq \frac{c}{N}e^{m\tau}v(x,t)\left(\frac{N}{c}e^{-m\tau}\frac{\partial f(\frac{s}{d},0)}{\partial v} - 1\right)$$

$$\leq \frac{c}{N}e^{m\tau}v(x,t)\left(R_0 - 1\right).$$

The above inequality holds automatically for v(x, t) = 0 and also observe that the inequality is strict for  $u(x, t) < \frac{s}{d}$  and v(x, t) > 0. Therefore,

$$\frac{\mathrm{d}W(t)}{\mathrm{d}t} \leq \int_{\Omega} \left( \frac{c}{N} e^{m\tau} v(x,t) \left( R_0 - 1 \right) - \frac{pb}{q} e^{m\tau} z(x,t) \right) \mathrm{d}x \leq 0.$$

Moreover,  $\frac{dW(t)}{dt} = 0$  if and only if v(x, t) = 0 and z(x, t) = 0. In fact, if  $v(x_0, t_0) \neq 0$ , then there exists a neighborhood  $N_{(x_0,t_0)}$  of  $(x_0,t_0)$  such that  $v(x,t) \neq 0$  for  $(x,t) \in N_{(x_0,t_0)}$ . Then by the observation,  $u(x,t) = \frac{s}{d}$  for  $(x,t) \in N_{(x_0,t_0)}$ . This, together with the first equation of (1.4) and Assumption (A1), implies that v(x,t) = 0 for  $(x,t) \in N_{(x_0,t_0)}$ , a contradiction. Then it is easy to see that the largest invariant subset of  $\frac{dW(t)}{dt} = 0$  is  $\{P_0\}$ . By LaSalle's Invariance Principle (see Theorem 5.3.1 in [50] or Theorem 3.4.7 in [51]), the infection-free steady state  $P_0$  is globally attractive. In particular, this together with Proposition 4.1, tells us that  $P_0$  is globally asymptotically stable when  $R_0 < 1$ .

#### 4.2. Stability of the immunity-free infected steady state $P_1$

Next we consider the stability of the immunity-free infected steady state  $P_1$ . For convenience of notations, denote

$$\begin{array}{ll} f_1 = f(u_1, v_1), & g_1 = g(u_1, w_1), & f_{1u} = \frac{\partial f(u_1, v_1)}{\partial u}, \\ f_{1v} = \frac{\partial f(u_1, v_1)}{\partial v}, & g_{1u} = \frac{\partial g(u_1, w_1)}{\partial u}, & g_{1w} = \frac{\partial g(u_1, w_1)}{\partial w}. \end{array}$$

**Theorem 4.3.** Suppose  $R_0 > 1$ . Then the immunity-free infected steady state  $P_1$  of (1.4) is locally asymptotically stable if  $R_1 < 1$  and unstable if  $R_1 > 1$ .

*Proof.* From (4.2), we know that the characteristic equation at  $P_1$  is given by

$$(\lambda - qw_1 + b + \mu_i D_2)\rho_i(\lambda) = 0, \ i \in \mathbb{N},$$

Mathematical Biosciences and Engineering

where

$$\rho_i(\lambda) = (\lambda + d + f_{1u} + g_{1u})(\lambda + \delta)(\lambda + c + \mu_i D_1) - [(\lambda + d)(\lambda + c + \mu_i D_1)g_{1w} + (\lambda + d)N\delta f_{1v}]e^{-(\lambda + m)\tau}.$$

Clearly, the eigenvalue  $\lambda = b(R_1 - 1) - \mu_i D_2 < 0$  for  $i \in \mathbb{N}$  when  $R_1 < 1$  but when  $R_1 > 1$ , with i = 0, we have a positive eigenvalue  $\lambda = b(R_1 - 1)$ . Thus  $P_1$  is unstable if  $R_1 > 1$ . Now, we assume that  $R_1 < 1$ . Then the stability of  $P_1$  is determined by the roots of  $\rho_i(\lambda) = 0$ , which is equivalent to

$$1 = \frac{\lambda + d}{\lambda + d + f_{1u} + g_{1u}} \left( \frac{g_{1w}}{\lambda + \delta} e^{-(\lambda + m)\tau} + \frac{N\delta f_{1v}}{(\lambda + \delta)(\lambda + c + \mu_i D_1)} e^{-(\lambda + m)\tau} \right).$$
(4.4)

We claim that all solutions of (4.4) have negative real parts. Otherwise, suppose that there exists  $i_1 \in \mathbb{N}$  such that (4.4) has a solution  $\lambda_1$  with  $\text{Re}(\lambda_1) \ge 0$ . Then

$$1 = \left| \frac{\lambda_{1} + d}{\lambda_{1} + d + f_{1u} + g_{1u}} \left( \frac{g_{1w}}{\lambda_{1} + \delta} e^{-m\tau} e^{-\lambda_{1}\tau} + \frac{N\delta f_{1v}}{(\lambda_{1} + \delta)(\lambda_{1} + c + \mu_{i_{1}}D_{1})} e^{-m\tau} e^{-\lambda_{1}\tau} \right) \right|$$

$$< \left| \frac{g_{1w}}{\lambda_{1} + \delta} e^{-m\tau} e^{-\lambda_{1}\tau} \right| + \left| \frac{N\delta f_{1v}}{(\lambda_{1} + \delta)(\lambda_{1} + c + \mu_{i_{1}}D_{1})} e^{-m\tau} e^{-\lambda_{1}\tau} \right|$$

$$< \frac{g_{1w}}{\delta} e^{-m\tau} + \frac{Nf_{1v}}{c} e^{-m\tau}.$$
(4.5)

However, from the steady state Eqs (3.1b) and (3.1c), we have

$$\frac{g(u_1, w_1)}{\delta w_1} e^{-m\tau} + \frac{Nf(u_1, v_1)}{cv_1} e^{-m\tau} = 1.$$

This and Assumption (A1) (v) together give us

$$\frac{g_{1w}}{\delta}e^{-m\tau} + \frac{Nf_{1v}}{c}e^{-m\tau} \le \frac{g(u_1, w_1)}{\delta w_1}e^{-m\tau} + \frac{Nf(u_1, v_1)}{cv_1}e^{-m\tau} = 1,$$

which is a contradiction with (4.5). This proves the claim and hence  $P_1$  is locally asymptotically stable when  $R_1 < 1 < R_0$ .

Before studying the global stability of  $P_1$ , we establish the persistence of infection.

From the linearized system at  $P_0$  (see (4.1)), we have the following cooperative system for (w, v),

$$\begin{cases} \frac{\partial w(x,t)}{\partial t} &= e^{-m\tau} \frac{\partial f(u_0,0)}{\partial v} v(x,t-\tau) + e^{-m\tau} \frac{\partial g(u_0,0)}{\partial w} w(x,t-\tau) - \delta w(x,t),\\ \frac{\partial v(x,t)}{\partial t} &= D_1 \Delta v(x,t) + N \delta w(x,t) - c v(x,t). \end{cases}$$
(4.6)

With similar arguments as those for Lemma 3 and Lemma 4 in Lou and Zhao [45], we can obtain the following results.

**Lemma 4.4.** There exists a principal eigenvalue  $\overline{\lambda}(u_0, \tau) \triangleq \overline{\lambda}(P_0, \tau)$  of (4.6) associated with a strongly positive eigenvector. Moreover,  $\overline{\lambda}(u_0, \tau)$  has the same sign as  $\lambda(u_0) \triangleq \overline{\lambda}(u_0, 0)$ .

**Lemma 4.5.**  $R_0 - 1$  and  $\lambda(u_0)$  have the same sign.

**Theorem 4.6.** Suppose  $R_1 \le 1 < R_0$ . Then the infection is persistent, that is, there exists  $\varepsilon > 0$  such that

$$\liminf_{t\to\infty} u(x,t,\phi) \ge \varepsilon, \quad \liminf_{t\to\infty} w(x,t,\phi) \ge \varepsilon, \quad \liminf_{t\to\infty} v(x,t,\phi) \ge \varepsilon$$

uniformly for all  $x \in \overline{\Omega}$ , where  $\phi \in W_1 := \{\phi \in C^+ : w(\cdot, 0) \neq 0 \text{ and } v(\cdot, 0) \neq 0\}$ .

Proof. Define

$$\partial \mathcal{W}_1 := \mathcal{C}^+ \setminus \mathcal{W}_1 = \{ \phi \in \mathcal{C}^+ : w(\cdot, 0) \equiv 0 \text{ or } v(\cdot, 0) \equiv 0 \}.$$

By Lemma 2.2 and the second equation of (1.4), we know that  $\Phi(t)W_1 \subseteq W_1$  for all  $t \ge 0$ . Denote

$$\mathcal{M}_{\partial} := \{ \phi \in \partial \mathcal{W}_1 : \Phi(t) \phi \in \partial \mathcal{W}_1 \text{ for } t \ge 0 \}.$$

**Claim 1.**  $\omega(\phi) = \{(u_0, 0, 0, 0)\}$  for  $\phi \in \mathcal{M}_{\partial}$ , where  $\omega(\phi)$  is the omega limit set of the orbit  $O^+(\phi) := \{\Phi(t)\phi : t \ge 0\}$ .

Since  $\phi \in \mathcal{M}_{\partial}$ , for all  $t \ge 0$ , either  $w(x, t, \phi) \equiv 0$  or  $v(x, t, \phi) \equiv 0$ . If  $w(x, t, \phi) \equiv 0$  for all  $t \ge 0$ , then  $\lim_{t \to \infty} v(x, t, \phi) = 0$  uniformly for  $x \in \overline{\Omega}$  from the third equation of (1.4). Now, suppose that  $w(x, t_1, \phi) \neq 0$ for some  $t_1 \ge 0$ . Then by Lemma 2.2,  $w(x, t, \phi) > 0$  for all  $t \ge t_1 + \tau$  and  $x \in \Omega$ . Thus  $v(x, t, \phi) \equiv 0$ for all  $t \ge t_1 + \tau$ . This, combined with the third equation of (1.4), implies that  $w(x, t, \phi) \equiv 0$  for  $x \in \overline{\Omega}$ and  $t \ge t_1 + \tau$ . Then, in either case,  $\lim_{t \to \infty} v(x, t, \phi) = \lim_{t \to \infty} w(x, t, \phi) = 0$  uniformly for  $x \in \overline{\Omega}$ . Thus u is asymptotic to

$$\frac{\partial u(x,t)}{\partial t} = s - du(x,t).$$

By Corollary 4.3 in [52], we get  $\lim_{t\to\infty} u(x, t, \phi) = u_0$  uniformly for  $x \in \overline{\Omega}$ . The above discussion tells us that  $w(x, t, \phi) \equiv 0$  for all *t* large enough. Then we can easily see from the fourth equation of (1.4) that  $\lim_{t\to\infty} z(x, t, \phi) = 0$  uniformly for  $x \in \overline{\Omega}$ . This proves  $\omega(\phi) = \{(u_0, 0, 0, 0)\}$ .

Since  $R_1 \le 1 < R_0$ , by Lemma 4.4 and Lemma 4.5, there exists a sufficiently small  $\varepsilon_0 > 0$  such that the following linear system

$$\begin{cases} \frac{\partial w(x,t)}{\partial t} &= e^{-m\tau} \left( \frac{\partial f(u_0,0)}{\partial v} - \varepsilon_0 \right) v(x,t-\tau) + e^{-m\tau} \left( \frac{\partial g(u_0,0)}{\partial w} - \varepsilon_0 \right) w(x,t-\tau) - (\delta + p\varepsilon_0) w(x,t), \\ \frac{\partial v(x,t)}{\partial t} &= D_1 \Delta v(x,t) + N \delta w(x,t) - c v(x,t) \end{cases}$$

has a positive principal eigenvalue  $\overline{\lambda}(u_0 - \varepsilon_0)$  with positive eigenfunction  $(w_{\varepsilon_0}, v_{\varepsilon_0})$ . By the continuity in Assumption (A1), there exists  $\delta_0 \in (0, \varepsilon_0]$  such that

$$\frac{\partial f(u,v)}{\partial v} \ge \frac{\partial f(u_0,0)}{\partial v} - \varepsilon_0 \quad \text{and} \quad \frac{\partial g(u,w)}{\partial w} \ge \frac{\partial g(u_0,0)}{\partial w} - \varepsilon_0$$

for all  $u_0 - \delta_0 \le u \le u_0 + \delta_0$ ,  $0 \le v \le \delta_0$ , and  $0 \le w \le \delta_0$ .

**Claim 2.**  $\{(u_0, 0, 0, 0)\}$  is a uniform weak repeller for  $W_1$  in the sense that

$$\limsup_{t \to \infty} \|\Phi(t)\phi - (u_0, 0, 0, 0)\| \ge \delta_0 \text{ for } \phi \in \mathcal{W}_1.$$

Suppose, by contradiction, there exists  $\phi_1^* \in W_1$  such that  $\limsup_{t \to \infty} \|\Phi(t)\phi_1^* - (u_0, 0, 0, 0)\| < \delta_0$ . Then there exists  $t_2 > 0$  such that  $u(x, t, \phi_1^*) > u_0 - \delta_0 \ge u_0 - \varepsilon_0$ ,  $w(x, t, \phi_1^*) \le \delta_0$ , and  $v(x, t, \phi_1^*) \le \delta_0$  for  $t \ge t_2$ 

and  $x \in \overline{\Omega}$ . It follows from Assumption (A1) and the choice of  $\delta_0$  that w and v satisfy

$$\begin{pmatrix}
\frac{\partial w(x,t)}{\partial t} \geq e^{-m\tau} \left( \frac{\partial f(u_0,0)}{\partial v} - \varepsilon_0 \right) v(x,t-\tau) + e^{-m\tau} \left( \frac{\partial g(u_0,0)}{\partial w} - \varepsilon_0 \right) w(x,t-\tau) - (\delta + p\varepsilon_0) w(x,t), \\
t \geq t_2, \ x \in \Omega, \\
\frac{\partial v(x,t)}{\partial t} = D_1 \Delta v(x,t) + N \delta w(x,t) - cv(x,t), \quad t \geq t_2, \ x \in \Omega, \\
\frac{\partial v(x,t)}{\partial t} = 0, \quad t \geq t_2, \quad x \in \partial \Omega.
\end{cases}$$
(4.7)

Due to  $w(x, t, \phi_1^*) > 0$  and  $v(x, t, \phi_1^*) > 0$  for t > 0 and  $x \in \Omega$ , there exists  $\kappa_1 > 0$  such that  $(w(x, t_2 + \theta, \phi_1^*), v(x, t_2 + \theta, \phi_1^*)) \ge \kappa_1 e^{\overline{\lambda}(u_0 - \varepsilon_0)(t_2 + \theta)}(w_{\varepsilon_0}(x), v_{\varepsilon_0}(x))$  for all  $x \in \Omega$  and  $\theta \in [-\tau, 0]$ . Then it follows from the comparison principle that  $w(x, t, \phi_1^*) \ge \kappa_1 e^{\overline{\lambda}(u_0 - \varepsilon_0)t} w_{\varepsilon_0}(x)$  and  $v(x, t, \phi_1^*) \ge \kappa_1 e^{\overline{\lambda}(u_0 - \varepsilon_0)t} v_{\varepsilon_0}(x)$  for all  $x \in \Omega$  and  $t \ge t_2$ , a contradiction to the fact that both  $w(x, t, \phi_1^*)$  and  $v(x, t, \phi_1^*)$  are bounded. This proves Claim 2.

Define a continuous function  $\mathcal{P}_1 : \mathcal{C}^+ \to [0, \infty)$  by

$$\mathcal{P}_1(\phi) := \min\left\{\min_{x\in\overline{\Omega}}\phi_2(x,0), \ \min_{x\in\overline{\Omega}}\phi_3(x,0)\right\} \text{ for all } \phi \in C^+.$$

Clearly,  $\mathcal{P}_1^{-1}(0, \infty) \subset \mathcal{W}_1$ , and  $\mathcal{P}_1$  has the property that if  $\mathcal{P}_1(\phi) = 0$  and  $\phi \in \mathcal{W}_1$  or  $\mathcal{P}_1(\phi) > 0$ , then  $\mathcal{P}_1(\Phi(t)\phi) > 0$  for all t > 0. Hence,  $\mathcal{P}_1$  is a generalized distance function for the semiflow  $\Phi(t)$  [53]. According to the above discussions, we obtain that any forward orbit of  $\Phi(t)$  in  $\mathcal{M}_{\partial}$  converges to  $(u_0, 0, 0, 0)$ , which is isolated in  $C^+$  and  $\mathcal{W}^s(u_0, 0, 0, 0) \cap \mathcal{W}_1 = \emptyset$ , where  $\mathcal{W}^s(u_0, 0, 0, 0)$  is the stable manifold of  $(u_0, 0, 0, 0)$ . Moreover, there is no cycle in  $\partial \mathcal{W}_1$  from  $(u_0, 0, 0, 0)$  to  $(u_0, 0, 0, 0)$ . Applying Theorem 3 in [53], we know that there exists an  $\bar{\varepsilon} > 0$  such that min $\{\mathcal{P}_1(\phi)\} > \bar{\varepsilon}$  for any  $\phi \in \mathcal{W}_1$ . It follows that

$$\liminf_{t\to\infty} w(x,t) \ge \bar{\varepsilon} \text{ and } \liminf_{t\to\infty} v(x,t) \ge \bar{\varepsilon} \text{ uniformly for all } x \in \Omega.$$

This combined with Lemma 2.2 finishes the proof with  $\varepsilon = \min\{\bar{\varepsilon}, \frac{s}{d+n_1+n_2}\}$ .

In order to study the global stability of  $P_1$ , define  $G : (0, \infty) \ni x \to x - 1 - \ln x$ . Obviously, G(x) > 0 for  $x \in (0, \infty)$  and *G* attains its global minimum only at x = 1. We also need the following assumption.

(A2) The nonlinear incidence functions f(u, v) and g(u, w) satisfy the following conditions.

(i) For any u > 0,

$$\begin{cases} \frac{v}{v_1} \le \frac{u_1 f(u, v)}{u f(u_1, v_1)} < 1 & \text{if } 0 < v < v_1, \\ 1 \le \frac{u_1 f(u, v)}{u f(u_1, v_1)} < \frac{v}{v_1} & \text{if } v_1 < v. \end{cases}$$

(ii) For any u > 0,

$$\begin{cases} \frac{w}{w_1} \le \frac{u_1 g(u, w)}{u g(u_1, w_1)} < 1 & \text{if } 0 < w < w_1, \\ 1 \le \frac{u_1 g(u, w)}{u g(u_1, w_1)} < \frac{w}{w_1} & \text{if } w_1 < w. \end{cases}$$

**Theorem 4.7.** Suppose that  $R_1 \le 1 < R_0$  and Assumption (A2) are satisfied. Then the immunity-free infected steady state  $P_1$  is globally attractive in

$$C_1^+ = \{ \phi \in C^+ | \text{there exists } t_3 \in \mathbb{R}^+ \text{ such that } w(\cdot, t_3, \phi) \neq 0 \text{ or } v(\cdot, t_3, \phi) \neq 0 \}.$$

In particular, it is globally asymptotically stable in  $C_1^+$  if further  $R_1 < 1$ .

*Proof.* According to Lemma 2.2 and Theorem 4.6, we know that there exists  $\varepsilon > 0$  such that  $\liminf_{t\to\infty} u(x,t,\phi) \ge \varepsilon$ ,  $\liminf_{t\to\infty} w(x,t,\phi) \ge \varepsilon$  for  $\phi \in C_1^+$ . Without loss of generality, we define a Lyapunov functional

$$L(t) = \int_{\Omega} L(x, t) \mathrm{d}x,$$

where

$$L(x,t) = u_1 G\left(\frac{u(x,t)}{u_1}\right) + e^{m\tau} w_1 G\left(\frac{w(x,t)}{w_1}\right) + \frac{f(u_1,v_1)}{cv_1} v_1 G\left(\frac{v(x,t)}{v_1}\right) + \frac{p}{q} e^{m\tau} z(x,t) + f(u_1,v_1) \int_{t-\tau}^t G\left(\frac{f(u(x,\theta),v(x,\theta))}{f(u_1,v_1)}\right) d\theta + g(u_1,w_1) \int_{t-\tau}^t G\left(\frac{g(u(x,\theta),w(x,\theta))}{g(u_1,w_1)}\right) d\theta.$$

Calculating the time derivative of L(x, t) along solutions of (1.4) yields

$$\begin{aligned} \frac{\partial L(x,t)}{\partial t} &= \left(1 - \frac{u_1}{u(x,t)}\right) [s - du(x,t) - f(u,v) - g(u,w)] + \frac{p}{q} e^{m\tau} [qw(x,t)z(x,t) - bz(x,t)] \\ &+ e^{m\tau} \left(1 - \frac{w_1}{w(x,t)}\right) [e^{-m\tau} f(u_{\tau},v_{\tau}) + e^{-m\tau} g(u_{\tau},w_{\tau}) - \delta w(x,t) - pw(x,t)z(x,t)] \\ &+ \frac{f(u_1,v_1)}{cv_1} \left(1 - \frac{v_1}{v(x,t)}\right) [D_1 \Delta v(x,t) + N \delta w(x,t) - cv(x,t)] + \frac{p}{q} e^{m\tau} D_2 \Delta z(x,t) \\ &+ f(u,v) - f(u_{\tau},v_{\tau}) + f(u_1,v_1) \ln \frac{f(u_{\tau},v_{\tau})}{f(u,v)} \\ &+ g(u,w) - g(u_{\tau},w_{\tau}) + g(u_1,w_1) \ln \frac{g(u_{\tau},w_{\tau})}{g(u,w)}. \end{aligned}$$

With

$$s = du_1 + f(u_1, v_1) + g(u_1, w_1), \ \delta = \frac{e^{-m\tau} f(u_1, v_1) + e^{-m\tau} g(u_1, w_1)}{w_1}, \ c = \frac{N \delta w_1}{v_1},$$

we have

$$\begin{aligned} \frac{\partial L(x,t)}{\partial t} \\ &= du_1 \left( 2 - \frac{u_1}{u(x,t)} - \frac{u(x,t)}{u_1} \right) + \frac{p}{q} e^{m\tau} (R_1 - 1) z(x,t) \\ &+ \frac{f(u_1,v_1)}{cv_1} \left( 1 - \frac{v_1}{v(x,t)} \right) D_1 \Delta v(x,t) + \frac{p}{q} e^{m\tau} D_2 \Delta z(x,t) - f(u_1,v_1) \frac{w(x,t)v_1}{v(x,t)w_1} \\ &+ f(u_1,v_1) \left[ 3 - \frac{u_1}{u(x,t)} - \frac{f(u_\tau,v_\tau)w_1}{f(u_1,v_1)w(x,t)} + \frac{f(u,v)u_1}{f(u_1,v_1)u(x,t)} - \frac{v(x,t)}{v_1} + \ln \frac{f(u_\tau,v_\tau)}{f(u,v)} \right] \\ &+ g(u_1,w_1) \left[ 2 - \frac{u_1}{u(x,t)} - \frac{g(u_\tau,w_\tau)w_1}{g(u_1,w_1)w(x,t)} + \frac{g(u,w)u_1}{g(u_1,w_1)u(x,t)} - \frac{w(x,t)}{w_1} + \ln \frac{g(u_\tau,w_\tau)}{g(u,w)} \right] \\ &= du_1 \left( 2 - \frac{u_1}{u(x,t)} - \frac{u(x,t)}{u_1} \right) + \frac{p}{q} e^{m\tau} (R_1 - 1) z(x,t) \end{aligned}$$

Mathematical Biosciences and Engineering

$$+\frac{f(u_{1},v_{1})}{cv_{1}}\left(1-\frac{v_{1}}{v(x,t)}\right)D_{1}\Delta v(x,t)+\frac{p}{q}e^{m\tau}D_{2}\Delta z(x,t)-f(u_{1},v_{1})G\left(\frac{w(x,t)v_{1}}{v(x,t)w_{1}}\right)\\+f(u_{1},v_{1})\left[G\left(\frac{f(u,v)u_{1}}{f(u_{1},v_{1})u(x,t)}\right)-G\left(\frac{v(x,t)}{v_{1}}\right)-G\left(\frac{u_{1}}{u(x,t)}\right)-G\left(\frac{f(u_{\tau},v_{\tau})w_{1}}{f(u_{1},v_{1})w(x,t)}\right)\right]\\+g(u_{1},w_{1})\left[G\left(\frac{g(u,w)u_{1}}{g(u_{1},w_{1})u(x,t)}\right)-G\left(\frac{w(x,t)}{w_{1}}\right)-G\left(\frac{u_{1}}{u(x,t)}\right)-G\left(\frac{g(u_{\tau},w_{\tau})w_{1}}{g(u_{1},w_{1})w(x,t)}\right)\right].$$

Clearly,

$$\int_{\Omega} du_1 \left( 2 - \frac{u(x,t)}{u_1} - \frac{u_1}{u(x,t)} \right) \mathrm{d}x \le 0$$

and

$$\int_{\Omega} \left( \frac{pb}{q} e^{m\tau} (R_1 - 1) z(x, t) \right) dx \le 0 \text{ since } R_1 \le 1.$$

Using the Divergence Theorem and the homogeneous Neumann boundary conditions of (1.5), we have

$$\int_{\Omega} \Delta v(x,t) dx = \int_{\partial \Omega} \frac{\partial v(x,t)}{\partial \vec{n}} dx = 0, \quad \int_{\Omega} \Delta z(x,t) dx = \int_{\partial \Omega} \frac{\partial z(x,t)}{\partial \vec{n}} dx = 0,$$

and

$$0 = \int_{\partial\Omega} \frac{1}{v(x,t)} \nabla v(x,t) \cdot \vec{n} \, dx$$
  
= 
$$\int_{\Omega} \nabla \left( \frac{1}{v(x,t)} \nabla v(x,t) \right) dx$$
  
= 
$$\int_{\Omega} \left( \frac{1}{v(x,t)} \Delta v(x,t) - \frac{1}{v^2(x,t)} \| \nabla v(x,t) \|^2 \right) dx.$$

The latter gives

$$\int_{\Omega} \frac{1}{\nu(x,t)} \Delta \nu(x,t) \mathrm{d}x = \int_{\Omega} \frac{1}{\nu^2(x,t)} \|\nabla \nu(x,t)\|^2 \mathrm{d}x \ge 0$$

and hence

$$\int_{\Omega} \frac{f(u_1, v_1)}{cv_1} \left(1 - \frac{v_1}{v(x, t)}\right) D_1 \Delta v(x, t) \mathrm{d}x \le 0.$$

To summarize, we have obtained

$$\begin{split} \frac{\mathrm{d}L(t)}{\mathrm{d}t} &\leq f(u_1, v_1) \int_{\Omega} \left[ G\left(\frac{f(u, v)u_1}{f(u_1, v_1)u(x, t)}\right) - G\left(\frac{v(x, t)}{v_1}\right) \right] \mathrm{d}x \\ &+ g(u_1, w_1) \int_{\Omega} \left[ G\left(\frac{g(u, w)u_1}{g(u_1, w_1)u(x, t)}\right) - G\left(\frac{w(x, t)}{w_1}\right) \right] \mathrm{d}x \\ &- g(u_1, w_1) \int_{\Omega} \left[ G\left(\frac{u_1}{u(x, t)}\right) + G\left(\frac{g(u_{\tau}, w_{\tau})w_1}{g(u_1, w_1)w(x, t)}\right) \right] \mathrm{d}x \\ &- f(u_1, v_1) \int_{\Omega} \left[ G\left(\frac{u_1}{u(x, t)}\right) + G\left(\frac{f(u_{\tau}, v_{\tau})w_1}{f(u_1, v_1)w(x, t)}\right) + G\left(\frac{w(x, t)v_1}{v(x, t)w_1}\right) \right] \mathrm{d}x. \end{split}$$

Mathematical Biosciences and Engineering

Note that the monotonicity of G(x) on each side of x = 1 and Assumption (A2) give us

$$G\left(\frac{f(u,v)u_1}{f(u_1,v_1)u(x,t)}\right) \le G\left(\frac{v(x,t)}{v_1}\right) \quad \text{and} \quad G\left(\frac{g(u,w)u_1}{g(u_1,w_1)u(x,t)}\right) \le G\left(\frac{w(x,t)}{w_1}\right).$$

Thus

$$\begin{aligned} \frac{\mathrm{d}L(t)}{\mathrm{d}t} &\leq -g(u_1, w_1) \int_{\Omega} \left[ G\left(\frac{u_1}{u(x, t)}\right) + G\left(\frac{g(u_\tau, w_\tau)w_1}{g(u_1, w_1)w(x, t)}\right) \right] \mathrm{d}x \\ &- f(u_1, v_1) \int_{\Omega} \left[ G\left(\frac{u_1}{u(x, t)}\right) + G\left(\frac{f(u_\tau, v_\tau)w_1}{f(u_1, v_1)w(x, t)}\right) + G\left(\frac{w(x, t)v_1}{v(x, t)w_1}\right) \right] \mathrm{d}x \\ &\leq 0. \end{aligned}$$

Moreover,  $\frac{dL(t)}{dt} = 0$  if and only if  $u(x,t) = u_1$ ,  $w(x,t) = w_1$ ,  $v(x,t) = v_1$ , and z(x,t) = 0. Then the largest invariant subset of  $\frac{dL(t)}{dt} = 0$  is  $\{P_1\}$ . By LaSalle's Invariance Principle (see Theorem 5.3.1 in [50] or Theorem 3.4.7 in [51]), the immunity-free infected steady state  $P_1$  is globally attractive in  $C_1^+$  when  $R_1 \le 1 < R_0$ . This, together with Theorem 4.3, implies that  $P_1$  is globally asymptotically stable in  $C_1^+$  if further  $R_1 < 1$ .

## 4.3. The stability of the infected-immune steady state $P_2$

For convenience of notations, denote

$$\begin{aligned} f_2 &= f(u_2, v_2), \qquad g_2 = g(u_2, w_2), \qquad f_{2u} = \frac{\partial f(u_2, v_2)}{\partial u}, \\ f_{2v} &= \frac{\partial f(u_2, v_2)}{\partial v}, \qquad g_{2u} = \frac{\partial g(u_2, w_2)}{\partial u}, \qquad g_{2w} = \frac{\partial g(u_2, w_2)}{\partial w} \end{aligned}$$

**Theorem 4.8.** If  $R_1 > 1$ , then the infected-immune steady state  $P_2$  is locally asymptotically stable.

*Proof.* According to (4.2), the characteristic equation at  $P_2$  is

$$0 = (\lambda + d + f_{2u} + g_{2u})(\lambda + c + \mu_i D_1)(\lambda + b - qw_2 + \mu_i D_2)(\lambda + \delta + pz_2) + qw_2 pz_2(\lambda + c + \mu_i D_1)(\lambda + d + f_{2u} + g_{2u}) - (\lambda + d)(\lambda + c + \mu_i D_1)(\lambda + b - qw_2 + \mu_i D_2)g_{2w}e^{-(\lambda + m)\tau} - (\lambda + d)(\lambda + b - qw_2 + \mu_i D_2)N\delta f_{2v}e^{-(\lambda + m)\tau}.$$
(4.8)

We claim that all roots of (4.8) have negative real parts. Otherwise, suppose for some  $i_2 \in \mathbb{N}$ , it has a root  $\lambda_2$  with  $\operatorname{Re}(\lambda_2) \ge 0$ . Since  $w_2 = \frac{b}{q}$ , we have

$$1 = \frac{(\lambda_2 + \mu_{i_2}D_2)(\lambda_2 + d)}{(\lambda_2 + d + f_{2u} + g_{2u})[(\lambda_2 + \mu_{i_2}D_2)(\lambda_2 + \delta + pz_2) + pbz_2]} \left(g_{2w}e^{-(\lambda_2 + m)\tau} + \frac{N\delta f_{2v}e^{-(\lambda_2 + m)\tau}}{\lambda_2 + c + \mu_{i_2}D_1}\right),$$

which implies

$$1 < \left| \frac{\lambda_2 + \mu_{i_2} D_2}{(\lambda_2 + \mu_{i_2} D_2)(\lambda_2 + \delta + pz_2) + pbz_2} \right| \times \left( g_{2w} e^{-m\tau} + \frac{N\delta f_{2v} e^{-m\tau}}{c} \right).$$

With similar arguments as those in the proof of Theorem 4.3, we can obtain

$$g_{2w}e^{-m\tau} + \frac{N\delta f_{2v}e^{-m\tau}}{c} \le \delta + pz_2.$$

Mathematical Biosciences and Engineering

Thus we have arrived at

$$< \left| \frac{\lambda_2 + \mu_{i_2} D_2}{(\lambda_2 + \mu_{i_2} D_2)(\lambda_2 + \delta + pz_2) + pbz_2} \right| \times (\delta + pz_2),$$

which is impossible as one can check that  $|(\lambda_2 + \mu_{i_2}D_2)(\lambda_2 + \delta + pz_2) + pbz_2| > |(\lambda_2 + \mu_{i_2}D_2)(\delta + pz_2)|$ . This completes the proof.

To establish the global stability of  $P_2$ , we need the persistence of immunity.

From the linearized system at  $P_1$  (see (4.1)), we have the following cooperative system for (w, v, z),

$$\begin{cases} \frac{\partial w(x,t)}{\partial t} &= e^{-m\tau} \frac{\partial f(u_1,v_1)}{\partial v} v(x,t-\tau) + e^{-m\tau} \frac{\partial g(u_1,w_1)}{\partial w} w(x,t-\tau) - (\delta + pz_1) w(x,t) - pw_1 z(x,t), \\ \frac{\partial v(x,t)}{\partial t} &= D_1 \Delta v(x,t) + N \delta w(x,t) - cv(x,t), \\ \frac{\partial z(x,t)}{\partial t} &= D_2 \Delta z(x,t) + qz_1 w(x,t) + (qw_1 - b) z(x,t). \end{cases}$$
(4.9)

With similar arguments as those for Lemma 3 and Lemma 4 in Lou and Zhao [45], we can obtain the following results.

**Lemma 4.9.** There exists a principal eigenvalue  $\hat{\lambda}(P_1, \tau)$  of (4.9) associated with a strongly positive eigenvector. Moreover,  $\hat{\lambda}(P_1, \tau)$  has the same sign as  $\hat{\lambda}(P_1, 0)$ .

**Lemma 4.10.**  $R_1 - 1$  and  $\hat{\lambda}(P_1, 0)$  have the same sign.

1

**Theorem 4.11.** Suppose that  $R_1 > 1$  (it is necessary that  $R_0 > 1$ ) and (A2) holds. Then the immunity is persistent, that is, there exists  $\epsilon > 0$  such that

$$\liminf_{t \to \infty} u(x, t, \phi) \ge \epsilon, \quad \liminf_{t \to \infty} w(x, t, \phi) \ge \epsilon, \quad \liminf_{t \to \infty} v(x, t, \phi) \ge \epsilon, \quad \liminf_{t \to \infty} z(x, t, \phi) \ge \epsilon$$

uniformly for all  $x \in \overline{\Omega}$ , where  $\phi \in W_2 := \{\phi \in C^+ : w(\cdot, 0) \neq 0, v(\cdot, 0) \neq 0, and z(\cdot, 0) \neq 0\}$ .

Proof. The proof is quite similar to that of Theorem 4.6. Denote

$$\partial W_2 := C^+ \setminus W_2 = \{ \phi \in C^+ : w(\cdot, 0) \equiv 0, \text{ or } v(\cdot, 0) \equiv 0, \text{ or } z(\cdot, 0) \equiv 0 \}.$$

Set  $M_0 = \{P_0\}$  and  $M_1 = \{P_1\}$ .

According to Lemma 2.2, we know that  $w(x, t, \phi) > 0$ ,  $v(x, t, \phi) > 0$ , and  $z(x, t, \phi) > 0$  for all t > 0and  $x \in \Omega$ ,  $\phi \in W_2$ , which implies that  $\Phi(t)W_2 \subseteq W_2$  for all  $t \ge 0$ . Define

$$\mathcal{M}^*_{\partial} := \{ \phi \in \partial \mathcal{W}_2 : \Phi(t) \phi \in \partial \mathcal{W}_2 \text{ for } t \ge 0 \}.$$

**Claim 3.** Let  $\phi \in \mathcal{M}^*_{\partial}$ . Then  $\omega(\phi) = M_0$  or  $M_1$ .

Sine  $\phi \in \mathcal{M}_{\partial}^*$ , for any  $t \ge 0$ , we have either  $w(x, t, \phi) \equiv 0$ , or  $v(x, t, \phi) \equiv 0$ , or  $z(x, t, \phi) \equiv 0$ . If  $z(x, t_4, \phi) \not\equiv 0$  for some  $t_4 \ge 0$ , then by Lemma 2.2,  $z(x, t, \phi) > 0$  for  $t > t_4$  and  $x \in \Omega$ . Then either  $w(x, t, \phi) \equiv 0$  or  $v(x, t, \phi) \equiv 0$  for each  $t > t_4$ . By the proof of Claim 1, we know that  $\omega(\phi) = M_0$ . Now, suppose that  $z(x, t, \phi) \equiv 0$  for all  $t \ge 0$ . If for each  $t \ge 0$ , either  $w(x, t, \phi) \equiv 0$  or  $v(x, t, \phi) \equiv 0$ , then by Claim 1,  $\omega(\phi) = M_0$ . If there exists  $\tilde{t} \ge 0$  such that  $w(x, \tilde{t}, \phi) \not\equiv 0$  and  $v(x, \tilde{t}, \phi) \not\equiv 0$ . Then by Theorem 4.6, there exists  $\xi > 0$  such that

$$\liminf_{t \to \infty} w(x, t, \phi) \ge \xi \text{ and } \liminf_{t \to \infty} v(x, t, \phi) \ge \xi \text{ uniformly in } \Omega.$$

Now consider the reduced system of (1.4) with z = 0. Modifying the Lyapunov functional L(t) in the proof of Theorem 4.7 by ignoring the term  $\frac{p}{q}e^{m\tau}z(x,t)$  in L(x,t), we can show that the solution of the reduced system converges to  $(u_1, w_1, v_1)$  and hence  $\omega(\phi) = M_1$ . This proves Claim 3.

**Claim 4.** Both  $M_0$  and  $M_1$  are uniform weak repellers for  $W_2$ . Since  $W_2 \subset W_1$ , by Claim 2,  $M_0$  is a uniform repeller for  $W_2$ . The proof of  $M_1$  being a uniform repeller of  $W_2$  is similar as that of Claim 2 by using Lemma 4.9 and Lemma 4.10. Therefore, we omit the detail here.

Define a continuous function  $\mathcal{P}_2 : \mathcal{C}^+ \to [0, \infty)$  by

$$\mathcal{P}_{2}(\phi) := \min\left\{\min_{x\in\overline{\Omega}}\phi_{2}(x,0), \ \min_{x\in\overline{\Omega}}\phi_{3}(x,0), \ \min_{x\in\overline{\Omega}}\phi_{4}(x,0)\right\} \text{ for } \phi \in C^{+}.$$

It is easy to see that  $\mathcal{P}_2^{-1}(0, \infty) \subset \mathcal{W}_2$ , and  $\mathcal{P}_2$  has the property that if  $\mathcal{P}_2(\phi) = 0$  and  $\phi \in \mathcal{W}_2$  or  $\mathcal{P}_2(\phi) > 0$ , then  $\mathcal{P}_2(\Phi(t)\phi) > 0$  for all t > 0. Thus  $\mathcal{P}_2$  is a generalized distance function for the semiflow  $\Phi(t)$ . As  $M_0$  and  $M_1$  are repellers, we know that both  $M_0$  and  $M_1$  are isolated, and  $\mathcal{W}^s(M_i) \cap \mathcal{W}_2 = \emptyset$  for i = 0 and 1. Moreover, no subset of  $\{M_0, M_1\}$  forms a cycle in  $\partial \mathcal{W}_2$ . By Smith and Zhao [53, Theorem 3], there exists a  $\bar{\epsilon} > 0$  such that min $\{\mathcal{P}_2(\phi)\} > \bar{\epsilon}$  for any  $\phi \in \mathcal{W}_2$ . Then as for Theorem 4.6, with  $\varepsilon = \min\{\bar{\epsilon}, \frac{s}{d+\eta_1+\eta_2}\}$  finishes the proof.

As for the global stability of  $P_2$ , we make the following assumption to establish the global stability of  $P_2$ .

(A3) The nonlinear incidence functions f(u, v) and g(u, w) satisfy the following conditions.

(i) For any u > 0,

$$\begin{cases} \frac{v}{v_2} \le \frac{u_2 f(u, v)}{u f(u_2, v_2)} < 1 & \text{if } 0 < v < v_2, \\ 1 \le \frac{u_2 f(u, v)}{u f(u_2, v_2)} < \frac{v}{v_2} & \text{if } v_2 < v. \end{cases}$$

(ii) For any u > 0,

$$\begin{cases} \frac{w}{w_2} \le \frac{u_2g(u,w)}{ug(u_2,w_2)} < 1 & \text{if } 0 < w < w_2, \\ 1 \le \frac{u_2g(u,w)}{ug(u_2,w_2)} < \frac{w}{w_2} & \text{if } w_2 < w. \end{cases}$$

**Theorem 4.12.** Suppose that  $R_1 > 1$  and Assumptions (A2) and (A3) are satisfied. Then the infectedimmune steady state  $P_2$  is globally asymptotically stable in

$$C_2^+ = \left\{ \phi \in C^+ \middle| \begin{array}{l} \text{there exists } t_5 \in \mathbb{R}^+ \text{ such that either } w(\cdot, t_5, \phi) \not\equiv 0 \text{ or } v(\cdot, t_5, \phi) \not\equiv 0, \\ \text{there exists } t_6 \in \mathbb{R}^+ \text{ such that } z(\cdot, t_6, \phi) \not\equiv 0 \end{array} \right\}$$

*Proof.* It follows from Lemma 2.2 and Theorem 4.11 that there exists an  $\varepsilon > 0$  such that

$$\liminf_{t\to\infty} u(x,t,\phi) \ge \varepsilon, \ \liminf_{t\to\infty} w(x,t,\phi) \ge \varepsilon, \ \liminf_{t\to\infty} v(x,t,\phi) \ge \varepsilon, \ \liminf_{t\to\infty} z(x,t,\phi) \ge \varepsilon$$

unfiormly in  $\overline{\Omega}$  and  $\phi \in C_2^+$ . Without loss of generality, we define a Lyapunov functional

$$I(t) = \int_{\Omega} I(x, t) \mathrm{d}x,$$

where

$$I(x,t) = u_2 G\left(\frac{u(x,t)}{u_2}\right) + e^{m\tau} w_2 G\left(\frac{w(x,t)}{w_2}\right) + \frac{f(u_2,v_2)}{cv_2} v_2 G\left(\frac{v(x,t)}{v_2}\right) + \frac{p}{q} e^{m\tau} z_2 G\left(\frac{z(x,t)}{z_2}\right)$$

Mathematical Biosciences and Engineering

$$+f(u_2, v_2) \int_{t-\tau}^t G\left(\frac{f(u(x,\theta), v(x,\theta))}{f(u_2, v_2)}\right) d\theta + g(u_2, w_2) \int_{t-\tau}^t G\left(\frac{g(u(x,\theta), w(x,\theta))}{g(u_2, w_2)}\right) d\theta.$$

Calculate the time derivative of I(x, t) along the solutions of (1.4) to get

$$\begin{aligned} \frac{\partial I(x,t)}{\partial t} &= \left(1 - \frac{u_2}{u(x,t)}\right) [s - du(x,t) - f(u,v) - g(u,w)] \\ &+ \frac{p}{q} e^{m\tau} \left(1 - \frac{z_2}{z(x,t)}\right) [qw(x,t)z(x,t) - bz(x,t)] \\ &+ e^{m\tau} \left(1 - \frac{w_2}{w(x,t)}\right) [e^{-m\tau} f(u_{\tau},v_{\tau}) + e^{-m\tau} g(u_{\tau},w_{\tau}) - \delta w(x,t) - pw(x,t)z(x,t)] \\ &+ \frac{f(u_2,v_2)}{cv_2} \left(1 - \frac{v_2}{v(x,t)}\right) [D_1 \Delta v(x,t) + N \delta w(x,t) - cv(x,t)] \\ &+ \frac{p}{q} e^{m\tau} \left(1 - \frac{z_2}{z(x,t)}\right) D_2 \Delta z(x,t) + f(u,v) - f(u_{\tau},v_{\tau}) + f(u_2,v_2) \ln \frac{f(u_{\tau},v_{\tau})}{f(u,v)} \\ &+ g(u,w) - g(u_{\tau},w_{\tau}) + g(u_2,w_2) \ln \frac{g(u_{\tau},w_{\tau})}{g(u,w)}. \end{aligned}$$

With the following relations,

$$s = du_{2} + f(u_{2}, v_{2}) + g(u_{2}, w_{2}),$$
  

$$\delta = \frac{e^{-m\tau}f(u_{2}, v_{2}) + e^{-m\tau}g(u_{2}, w_{2}) - pw_{2}z_{2}}{w_{2}},$$
  

$$c = \frac{N\delta w_{2}}{v_{2}},$$
  

$$w_{2} = \frac{b}{q},$$

we get

$$\begin{aligned} \frac{\partial I(x,t)}{\partial t} &= du_2 \left( 2 - \frac{u_2}{u(x,t)} - \frac{u(x,t)}{u_2} \right) + \frac{f(u_2,v_2)}{cv_2} \left( 1 - \frac{v_2}{v(x,t)} \right) D_1 \Delta v(x,t) \\ &+ \frac{p}{q} e^{m\tau} \left( 1 - \frac{z_2}{z(x,t)} \right) D_2 \Delta z(x,t) - f(u_2,v_2) \frac{w(x,t)v_2}{v(x,t)w_2} \\ &+ f(u_2,v_2) \left[ 3 - \frac{u_2}{u(x,t)} - \frac{f(u_\tau,v_\tau)w_2}{f(u_2,v_2)w(x,t)} + \frac{f(u,v)u_2}{f(u_2,v_2)u(x,t)} - \frac{v(x,t)}{v_2} + \ln \frac{f(u_\tau,v_\tau)}{f(u,v)} \right] \\ &+ g(u_2,w_2) \left[ 2 - \frac{u_2}{u(x,t)} - \frac{g(u_\tau,w_\tau)w_2}{g(u_2,w_2)w(x,t)} + \frac{g(u,w)u_2}{g(u_2,w_2)u(x,t)} - \frac{w(x,t)}{w_2} + \ln \frac{g(u_\tau,w_\tau)}{g(u,w)} \right]. \end{aligned}$$

Then

$$\frac{\mathrm{d}I(t)}{\mathrm{d}t} = \int_{\Omega} du_2 \left( 2 - \frac{u_2}{u(x,t)} - \frac{u(x,t)}{u_2} \right) \mathrm{d}x + \int_{\Omega} \frac{f(u_2,v_2)}{cv_2} \left( 1 - \frac{v_2}{v(x,t)} \right) D_1 \Delta v(x,t) \mathrm{d}x + \int_{\Omega} \frac{p}{q} e^{m\tau} \left( 1 - \frac{z_2}{z(x,t)} \right) D_2 \Delta z(x,t) \mathrm{d}x - f(u_2,v_2) \int_{\Omega} G\left( \frac{w(x,t)v_2}{v(x,t)w_2} \right) \mathrm{d}x$$

Mathematical Biosciences and Engineering

$$+f(u_{2},v_{2})\int_{\Omega} \left[ G\left(\frac{f(u,v)u_{2}}{f(u_{2},v_{2})u(x,t)}\right) - G\left(\frac{v(x,t)}{v_{2}}\right) - G\left(\frac{u_{2}}{u(x,t)}\right) - G\left(\frac{f(u_{\tau},v_{\tau})w_{2}}{f(u_{2},v_{2})w(x,t)}\right) \right] dx \\ +g(u_{2},w_{2})\int_{\Omega} \left[ G\left(\frac{g(u,w)u_{2}}{g(u_{2},w_{2})u(x,t)}\right) - G\left(\frac{w(x,t)}{w_{2}}\right) - G\left(\frac{u_{2}}{u(x,t)}\right) - G\left(\frac{g(u_{\tau},w_{\tau})w_{2}}{g(u_{2},w_{2})w(x,t)}\right) \right] dx.$$

Similarly as in the proof of Theorem 4.7, we can show

$$\begin{split} \int_{\Omega} du_2 \left( 2 - \frac{u(x,t)}{u_2} - \frac{u_2}{u(x,t)} \right) \mathrm{d}x &\leq 0, \\ \int_{\Omega} \frac{f(u_2,v_2)}{cv_2} \left( 1 - \frac{v_2}{v(x,t)} \right) D_1 \Delta v(x,t) \mathrm{d}x &\leq 0, \\ \int_{\Omega} \frac{p}{q} e^{m\tau} \left( 1 - \frac{z_2}{z(x,t)} \right) D_2 \Delta z(x,t) \mathrm{d}x &\leq 0, \\ G\left( \frac{f(u,v)u_2}{f(u_2,v_2)u(x,t)} \right) &\leq G\left( \frac{v(x,t)}{v_2} \right) \\ G\left( \frac{g(u,w)u_2}{g(u_2,w_2)u(x,t)} \right) &\leq G\left( \frac{w(x,t)}{w_2} \right) \end{split}$$

Therefore, we have  $\frac{dI(t)}{dt} \le 0$ . Moreover,  $\frac{dI(t)}{dt} = 0$  if and only if  $u(x, t) = u_2$ ,  $w(x, t) = w_2$ ,  $v(x, t) = v_2$ ,  $z(x, t) = z_2$ . Then the largest invariant subset of  $\frac{dI(t)}{dt} = 0$  is  $\{P_2\}$ . By LaSalle's Invariance Principle (see Theorem 5.3.1 in [50] or Theorem 3.4.7 in [51]), the infected-immune steady state  $P_2$  is globally attractive in  $C_2^+$ . This, together with Theorem 4.8, implies the global asymptotic stability of  $P_2$  in  $C_2^+$ .

## 5. Numerical simulations

In this section, we perform some numerical simulations to illustrate the results obtained in section 4. Let  $f(u, v) = \frac{\beta_1 uv}{1+\alpha_1 v}$  and  $g(u, w) = \frac{\beta_2 uw}{1+\alpha_2 w}$ . One can easily verify that *f* and *g* satisfy (A1)–(A3). Then the model (1.4) becomes

$$\begin{cases} \frac{\partial u(x,t)}{\partial t} = s - du(x,t) - \frac{\beta_1 u(x,t)v(x,t)}{1 + \alpha_1 v(x,t)} - \frac{\beta_2 u(x,t)w(x,t)}{1 + \alpha_2 w(x,t)}, & x \in \Omega, t > 0, \\ \frac{\partial w(x,t)}{\partial t} = e^{-m\tau} \left( \frac{\beta_1 u(x,t-\tau)v(x,t-\tau)}{1 + \alpha_1 v(x,t-\tau)} + \frac{\beta_2 u(x,t-\tau)w(x,t-\tau)}{1 + \alpha_2 w(x,t-\tau)} \right) \\ -\delta w(x,t) - pw(x,t)z(x,t), & x \in \Omega, t > 0, \\ \frac{\partial v(x,t)}{\partial t} = D_1 \Delta v(x,t) + N \delta w(x,t) - cv(x,t), & x \in \Omega, t > 0, \\ \frac{\partial z(x,t)}{\partial t} = D_2 \Delta z(x,t) + qw(x,t)z(x,t) - bz(x,t), & x \in \Omega, t > 0, \end{cases}$$
(5.1)

subject to the homogeneous Neumann boundary conditions

$$\frac{\partial v}{\partial \vec{n}} = 0, \ \frac{\partial z}{\partial \vec{n}} = 0, \ x \in \partial \Omega, \ t > 0.$$

For (5.1), the basic reproduction number of infection is given by

$$R_0 = \frac{N\beta_1 s}{cd} e^{-m\tau} + \frac{\beta_2 s}{\delta d} e^{-m\tau}$$

Mathematical Biosciences and Engineering

and the basic reproduction number of immunity is given by

$$R_1 = \frac{qw_1}{b} = \frac{q\left(B_2 + \sqrt{B_2^2 - 4B_1B_3}\right)}{2bB_1},$$

where

$$B_1 = N\delta^2 e^{m\tau} (\beta_1 \alpha_2 + \beta_2 \alpha_1 + \alpha_1 \alpha_2 d) > 0,$$
  

$$B_2 = \delta d e^{m\tau} (N\delta\alpha_1 + c\alpha_2) - N\delta\beta_1 \alpha_2 s + N\delta^2 \beta_1 e^{m\tau} - N\delta\beta_2 \alpha_1 s + \delta e^{m\tau} \beta_2 c,$$
  

$$B_3 = -dc\delta e^{m\tau} (R_0 - 1) < 0 \text{ since } R_0 > 1.$$

For simulations, we take  $\alpha_1 = 0.01$ ,  $\alpha_2 = 0.01$ ,  $D_1 = 0.0017$ ,  $D_2 = 0.0001$ , and the values of the other parameters are summarized in Table 1. Moreover,  $\Omega = [0, 4]$  and the initial condition used is

$$u(x,\theta) = 23 + 0.2 \cos \frac{\pi x}{2}, \qquad w(x,\theta) = 0.7 + 0.2 \cos \frac{\pi x}{2}, v(x,\theta) = 3 + 0.2 \cos \frac{\pi x}{2}, \qquad z(x,\theta) = 2 + 0.2 \cos \frac{\pi x}{2}$$

for  $x \in [0, 4]$  and  $\theta \in [-0.5, 0]$ .

Parameters	Ranges	value	Units	References
S	0 ~ 10	10	cells ml <sup>-1</sup> day <sup>-1</sup>	[54]
d	$0.0001 \sim 0.2$	0.01	$day^{-1}$	[22]
$eta_1$	$4.6 \times 10^{-8} \sim 0.5$	variable	$ml^{-1}day^{-1}$	[55]
$eta_2$	$1 \times 10^{-5} \sim 0.7$	$2.4 \times 10^{-5}$	$ml^{-1}day^{-1}$	[39]
т	$\alpha \in [d, \delta]$	0.05	$day^{-1}$	[55]
au	$0 \sim 1.5$	0.5	days	[55]
δ	$0.00019 \sim 1.4$	1	$day^{-1}$	[22]
р	$0.0001 \sim 4.048$	0.024	$ml^{-1}day^{-1}$	[22, 55]
N	6.25 ~ 23599.9	2000	viron cells <sup>-1</sup>	[22]
С	2 ~ 36	23	$day^{-1}$	[22, 39]
q	$0.0051 \sim 3.912$	0.15	$day^{-1}$	[22]
b	$0.004 \sim 8.087$	0.5	$day^{-1}$	[22, 39]

 Table 1. Parameter values for simulation.

Firstly, we take  $\beta_1 = 1 \times 10^{-5}$ . Then  $R_0 = 0.8715 < 1$ . By Theorem 4.2, the infection-free steady state  $P_0 = (1000, 0, 0, 0)$  is globally asymptotically stable (see Figure 1).

Next, we choose  $\beta_1 = 2.4 \times 10^{-5}$ . Then  $R_0 = 2.0588 > 1$  and  $R_1 = 0.2989 < 1$ . From Theorem 4.7, the immunity-free infected steady state  $P_1 = (897.8483, 0.9963, 86.6344, 0)$  is globally asymptotically stable (see Figure 2).

Finally, with  $\beta_1 = 8.4 \times 10^{-5}$ , we get  $R_0 = 7.1474 > 1$  and  $R_1 = 1.1594 > 1$ . By Theorem 4.12, the infected-immune steady state  $P_2 = (609.8631, 3.3333, 289.8550, 5.8964)$  is globally asymptotically stable (see Figure 3).



**Figure 1.** When  $R_0 < 1$ , the infection-free steady state  $P_0$  is globally asymptotically stable. Parameter values are given in the text.



**Figure 2.** When  $R_0 = 2.0588 > 1$  and  $R_1 = 0.2989 < 1$ , the immunity-free infected steady state  $P_1$  is globally asymptotically stable. See the text for the parameter values.



**Figure 3.** When  $R_1 > 1$ , the infected-immune steady state  $P_2$  is globally asymptotically stable. See the text for the parameter values.

## 6. Conclusions

In this paper, we have proposed and studied a reaction-diffusion virus infection model by incorporating time delays, general incidence functions, and cell-to-cell transmission.

We have proved that the global dynamics of system (1.4)–(1.6) is determined by the basic reproduction number of infection  $R_0$  and the basic reproduction number of immunity  $R_1$ . By analyzing the characteristic equations and constructing Lyapunov functionals, we have obtained the following conclusions: if  $R_0 < 1$ , then the infected-free steady state  $P_0$  is globally asymptotically stable; if  $R_1 \le 1 < R_0$ , then the immunity-free infected steady state  $P_1$  is globally asymptotically stable under additional Assumption (A2); if  $R_1 > 1$ , then the infected-immune steady state  $P_2$  is globally asymptotically stable under additional Assumptions (A2) and (A3). We mention that most commonly used incidences satisfy (A1)–(A3). Some examples are the Holling type II incidence  $f(u, v) = \frac{\beta uv}{1+\alpha v}$  [40], Beddington-DeAnglis incidence [41], and  $f(u, v) = ku \ln(1 + \frac{\beta v}{k})$  [56].

### Acknowledgements

Chen is supported by NSERC of Canada. Wang is supported by the NSFC (No. 11771374), the Nanhu Scholars Program for Young Scholars of Xinyang Normal University.

## **Conflict of interests**

The authors declare that there is no conflict of interest.

## References

- 1. M. A. Nowak, S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, H. McDade, Viral dynamics in hepatitis B virus infection, *Proc. Natl. Acad. Sci. USA*, **93** (1996), 4398–4402.
- 2. M. A. Nowak, R. M. May, *Virus dynamics: Mathematical principles of immunology and virology*, Oxford University Press, 2000.
- 3. J. Guedj, A. U. Neumann, Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics, *J. Theoret. Biol.*, **267** (2010), 330–340.
- 4. L. Rong, A. S. Pereslon, Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents, *Math. Biosci.*, **245** (2013), 22–30.
- 5. R. V. Culshaw, S. Ruan, G. Webb, A mathematical model of cell-to-cell spread of HIV-1 that includes a time delay, *J. Math. Biol.*, **46** (2003), 425–444.
- 6. P. K. Srivastava, M. Banerjee, P. Chandra, A primary infection model for HIV and immune response with two discrete time delays, *Differ. Equ. Dyn. Syst.*, **18** (2010), 385–399.
- 7. X. Wang, X. Song, S. Tang, L. Rong, Dynamics of an HIV model with multiple infection stages and treatment with different drug classes, *Bull. Math. Biol.*, **78** (2016), 322–349.
- 8. X. Wang, G. Mink, D. Lin, X. Song, L. Rong, Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy, *J. Theoret. Biol.*, **416** (2017), 16–27.
- 9. M. Y. Li, H. Shu, Impact of intracellular delays and target-cell dynamics on in vivo viral infections, *SIAM J. Appl. Math.*, **70** (2010), 2434–2448.
- M. Y. Li, H. Shu, Global dynamics of a mathematical model for HTLV-I infection of CD4<sup>+</sup> T cells with delayed CTL response, *Nonlinear Anal. Real World Appl.*, 13 (2012), 1080–1092.
- 11. H. Zhao, S. Liu, A mathematical model of HTLV-I infection with nonlinear incidence and two time delays, *Commun. Math. Biol. Neurosci.*, **2016** (2016).
- 12. M. A. Nowak, C. R. M. Bangham, Population dynamics of immune responses to persistent viruses, *Science*, **272** (1996), 74–79.
- 13. K. Allali, S. Harroudi, D. F. M. Torres, Analysis and optimal control of an intracellular delayed HIV model with CTL immune response, *Math. Comput. Sci.*, **12** (2018), 111–127.
- 14. X. Wang, Y. Tao, Lyapunov function and global properties of virus dynamics with CTL immune response, *Int. J. Biomath.*, **1** (2008), 443–448.
- 15. J. Li, K. Men, Y. Yang, D. Li, Dynamical analysis on a chronic hepatitis C virus infection model with immune response, *J. Theoret. Biol.*, **365** (2015), 337–346.
- 16. A. M. Elaiw, A. A. Raezah, K. Hattaf, Stability of HIV-1 infection with saturated virus-target and infected-target incidences and CTL immune response, *Int. J. Biomath.*, **10** (2017), 1750070.
- A. V. M. Herz, S. Bonhoeffer, R. M. Anderson, R. M. May, M. A. Nowak, Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay, *Proc. Natl. Acad. Sci. USA*, 93 (1996), 7247–7251.

- H. Shu, L. Wang, J. Watmough, Global stability of a nonlinear viral infection model with infinitely distributed intracellular delays and CTL immune responses, *SIAM J. Appl. Math.*, **73** (2013), 1280–1302.
- 19. Y. Liu, C. Wu, Global dynamics for an HIV infection model with Crowley-Martin functional response and two distributed delays, *J. Syst. Sci. Complex.*, **31** (2018), 385–395.
- 20. H. Zhu, X. Zou, Dynamics of a HIV-1 infection model with cell-mediated immune response and intracellular delay, *Discrete Contin. Dyn. Syst. Ser. B*, **12** (2009), 511–524.
- 21. X. Wang, S. Liu, A class of delayed viral models with saturation infection rate and immune response, *Math. Methods Appl. Sci.*, **36** (2013), 125–142.
- B. Li, Y. Chen, X. Lu, S. Liu, A delayed HIV-1 model with virus waning term, *Math. Biosci. Eng.*, 13 (2016), 135–157.
- 23. O. T. Fackler, T. T. Murooka, A. Imle, T. R. Mempel, Adding new dimensions: towards an integrative understanding of HIV-1 spread, *Nat. Rev. Microbiol.*, **12** (2014), 563–574.
- 24. K. Wang, W. Wang, Propagation of HBV with spatial dependence, *Math. Biosci.*, **210** (2007), 78–95.
- 25. R. Xu, Z. Ma, An HBV model with diffusion and time delay, J. Theoret. Biol., 257 (2009), 499–509.
- 26. C. C. McCluskey, Y. Yang, Global stability of a diffusive virus dynamics model with general incidence function and time delay, *Nonlinear Anal. Real World Appl.*, **25** (2015), 64–78.
- 27. C. M. Brauner, D. Jolly, L. Lorenzi, R. Thiebaut, Heterogeneous viral environment in an HIV spatial model, *Discrete Contin. Dyn. Syst. Ser. B*, **15** (2011), 545–572.
- 28. Y. Zhang, Z. Xu, Dynamics of a diffusive HBV model with delayed Beddington-DeAngelis response, *Nonlinear Anal. Real World Appl.*, **15** (2014), 118–139.
- Y. Yang, Y. Xu, Global stability of a diffusive and delayed virus dynamics model with Beddington-DeAngelis incidence function and CTL immune response, *Comput. Math. Appl.*, **71** (2016), 922– 930.
- W. Hübner, G. P. McNerney, P. Chen, B. M. Dale1, R. E. Gordon, F. Y. S. Chuang, et al., Quantitative 3D video microscopy of HIV transfer across T cell virological synapses, *Science*, 323 (2009), 1743–1747.
- P. Zhong, L. M. Agosto, J. B. Munro, W. Mothes, Cell-to-cell transmission of viruses, *Curr. Opin. Virol.*, 3 (2013), 44–50.
- 32. N. Martin, Q. Sattentau, Cell-to-cell HIV-1 spread and its implications for immune evasion, *Curr. Opin. HIV AIDS*, **4** (2009), 143–149.
- C. Zhang, S. Zhou, E. Groppelli, P. Pellegrino, I. Williams, P. Borrow, Hybrid spreading mechanisms and T cell activation shape the dynamics of HIV-1 infection, *PLoS Comput. Biol.*, 11 (2015), e1004179.
- A. Sigal, J. T. Kim, A. B. Balazs, E. Dekel, A. Mayo, R. Milo, et al., Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy, *Nature*, 477 (2011), 95–98.

- 35. X. Lai, X. Zou, Modeling HIV-1 virus dynamics with both virus-to-cell infection and cell-to-cell transmission, *SIAM J. Appl. Math.*, **74** (2014), 898–917.
- 36. X. Lai, X. Zou, Modeling cell-to-cell spread of HIV-1 with logistic target cell growth, *J. Math. Anal. Appl.*, **426** (2015), 563–584.
- X. Wang, S. Tang, X. Song, L. Rong, Mathematical analysis of an HIV latent infection model including both virus-to-cell infection and cell-to-cell transmission, *J. Biol. Dyn.*, **11** (2017), 455– 483.
- H. Shu, Y. Chen, L. Wang, Impacts of the cell-free and cell-to-cell infection modes on viral dynamics, J. Dyn. Differ. Equ., 30 (2018), 1817–1836.
- 39. A. Debadatta, B. Nandadulal, Analysis and computation of multi-pathways and multi-delays HIV-1 infection model, *Appl. Math. Model.*, **54** (2018), 517–536.
- 40. X. Song, A. U. Neumann, Global stability and periodic solution of the viral dynamics, *J. Math. Anal. Appl.*, **329** (2007), 281–297.
- 41. X. Wang, Y. Tao, X. Song, Global stability of a virus dynamics model with Beddington-DeAngelis incidence rate and CTL immune response, *Nonlinear Dynam.*, **66** (2011), 825–830.
- 42. H. Sun, J. Wang, Dynamics of a diffusive virus model with general incidence function, cell-to-cell transmission and time delay, *Comput. Math. Appl.*, **77** (2019), 284–301.
- 43. R. H. Martin, H. L. Smith, Abstract functional-differential equations and reaction-diffusion systems, *Trans. Amer. Math. Soc.*, **321** (1990), 1–44.
- 44. Y. Gao, J. Wang, Threshold dynamics of a delayed nonlocal reaction-diffusion HIV infection model with both cell-free and cell-to-cell transmissions, *J. Math. Anal. Appl.*, **488** (2020), 124047.
- 45. Y. Lou, X. Zhao, A reaction-diffusion malaria model with incubation period in the vector population, *J. Math. Biol.*, **62** (2011), 543–568.
- 46. M. H. Protter, H. F. Weinberger, *Maximum principles in differential equations*, Springer-Verlag, 1984.
- 47. J. Wu, *Theory and applications of partial functional differential equations*, Springer, New York, 1996.
- 48. J. K. Hale, *Asymptotic behavior of dissipative systems*, American Mathematical Society, Providence, 1988.
- 49. W. Wang, X. Zhao, Basic reproduction numbers for reaction-diffusion epidemic models, *SIAM J. Appl. Dyn. Syst.*, **11** (2012), 1652–1673.
- 50. J. K. Hale, S. M. Verduyn Lunel, *Introduction to functional differential equations*, Springer-Verlag, 1993.
- 51. J. LaSalle, S. Lefschetz, Stability by Lyapunov's direct method, with applications, in *Mathematics in Science and Engineering*, Academic Press, 1961.
- 52. H. R. Thieme, Convergence results and a Poincaré-Bendixson trichotomy for asymptotically autonomous differential equations, *J. Math. Biol.*, **30** (1992), 755–763.
- 53. H. L. Smith, X. Zhao, Robust persistence for semidynamical systems, *Nonlinear Anal.*, **47** (2001), 6169–6179.

- 54. P. W. Nelson, J. D. Murray, A. S. Perelson, A model of HIV-1 pathogenesis that includes an intracellular delay, *Math. Biosci.*, **163** (2000), 201–215.
- 55. K. A. Pawelek, S. Liu, F. Pahlevani, L. Rong, A model of HIV-1 infection with two time delays: mathematical analysis and comparison with patient data, *Math. Biosci.*, **235** (2012), 98–109.
- 56. H. McCallum, N. Barlow, J. Hone, How should pathogen transmission be modelled? *Trends Ecol. Evol.*, **16** (2001), 295–300.



© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)